アメリカ合衆国
証券取引委員会
ワシントン, D.C. 20549
フォーム
(マーク ワン)
四半期の終了日
または
__________から__________への移行期間のために
委員会
ファイル番号：
(定款に指定された登録者の正確な名称)
(州 またはその他の管轄区域の 法人設立または組織) |
(I.R.S. 雇用者 識別 番号.) | |
| (主な経営オフィスの住所) | (郵便番号 ) |
(登録者の 電話番号、地域番号を含む)
証券 法第12(b)条に基づいて登録された:
| 各クラスのタイトル: | 取引シンボル | 登録されている各取引所の名称: | ||
チェックマークで示してください。
登録者が過去12ヶ月（または登録者がその報告を提出することを要求されていたより短い期間）に、1934年の証券取引法の第13条または第15(d)条に基づいて提出する必要のあるすべての報告書を提出した（1）か、また（2）過去90日間その提出要件に従っていたかどうか。
チェックマークで、登録者が過去12ヶ月間（または登録者がそのようなファイルを提出することを要求されたより短い期間の）に
規則405の下で提出が要求されるすべてのインタラクティブデータファイルを電子的に提出したかどうかを示してください。
チェックマークで、登録者が大規模加速開示者、加速開示者、非加速開示者、中小規模報告会社、または新興成長会社であるかを示してください。「大規模加速開示者」、「加速開示者」、「中小規模報告会社」、「新興成長会社」の定義については、ルール120億2を参照してください。
| 大規模加速企業 | ☐ | 加速企業 | ☐ | |
| ☒ | 小規模 開示会社 | |||
| 新興成長企業 |
新しいまたは改訂された財務会計基準の遵守に関する拡張移行期間を使用しないことを選択した場合、成長途上の企業であるかどうかを確認してください。（ Exchange Act 第13(a)条に基づく。）
書式に従い、登録者が大規模加速提出者、加速提出者、非加速提出者、より小規模な報告会社、または新興成長企業であるかどうかチェックマークで示してください。策定法12b-2の「大規模加速ファイラー」「加速ファイラー」「小規模報告会社」「新興成長企業」の定義については、参照してください。
2024年8月19日現在、 普通株式（クラスA）の1株あたり$のパー価値で 登録者が発行し、流通しているシェア（「クラスA普通株式」）がありました。
FOXO テクノロジーズ株式会社
フォーム 2024年6月30日に終了した四半期の10-Q
目次
| PART I - 財務情報： | ||
| 項目 1. | 1 | |
| 2024年6月30日および2023年12月31日時点の未監査の簡略化された連結貸借対照表 | 1 | |
| 2024年および2023年の6月30日までの3か月および6か月の未監査の簡略化された連結損益計算書 | 2 | |
| 2024年および2023年の6か月間の各四半期における未監査の簡略化された連結株主（赤字）資本の変動計算書 | 3 | |
| 2024年および2023年の6か月間の未監査の簡略化された連結キャッシュフロー計算書 | 5 | |
| 未監査の簡約合算財務諸表の注記 | 6 | |
| 項目 2. | 経営者の財務状態及び業績の分析と討論 | 32 |
| 項目 3。 | 市場リスクに関する定量的および定性的開示 | 44 |
| 項目 4. | 管理と手続き | 45 |
| PARt II - その他の情報: | ||
| 項目 1. | 法的手続き | 46 |
| 項目 5. | その他の情報 | 46 |
| 項目 6. | 付属書類 | 46 |
| 署名 | 47 | |
| i |
特別な
将来の見通しに関する声明及びその他の情報
この報告書に含まれる
この 四半期報告書（フォーム10-Q）、またはこの報告書、およびここに参照として組み込まれている文書には、1933年証券法（「証券法」）の第27A節および1934年証券取引法（「取引所法」）の第21E節の意味における前向きな声明が含まれています。 これには、制限なく、財務および業績指標の推定および予測、市場機会およびシェアの予測、当社の製品およびサービスの顧客に対する潜在的な利益および商業的魅力、当社のマーケティングおよび拡張戦略の潜在的な成功、ビジネスの組み合わせの潜在的な利益の実現（株主価値およびこの報告書で特定されているその他のビジネスの側面に関して含まれる）および、時折証券取引委員会に提出する他の報告書についての声明が含まれています。この報告書に含まれる当社のビジネス、財務結果、財務状態および運営についての、歴史的事実に基づかない声明は、前向きな声明と見なされる可能性があります。これらの前向きな声明は、未来の出来事についての当社の意図、計画、期待、仮定および信念を表しており、リスク、不確実性およびその他の要因の影響を受けます。
Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” or similar expressions are intended to identify forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or other events occur in the future. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described in Part I., Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 6, 2024.
Unless expressly indicated or the context requires otherwise, the terms “FOXO,” the “Company,” “we,” “us” or “our” in this Annual Report refer to FOXO Technologies Inc., a Delaware corporation, and, where appropriate, its subsidiaries.
| ii |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
FOXO technologies inc. and subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
| June 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Account receivable, net | ||||||||
| Prepaid expenses | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use lease asset | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Related parties’ payables and promissory notes | ||||||||
| Notes payable | ||||||||
| Accrued severance | ||||||||
| Accrued settlement | ||||||||
| Right-of-use lease liability | ||||||||
| Accrued and other liabilities | ||||||||
| Total current liabilities | ||||||||
| Warrant liabilities | ||||||||
| Related party payable | ||||||||
| Right-of-use lease liability, non-current | ||||||||
| Other liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders’ deficit | ||||||||
| Preferred stock, $ par value; shares authorized, issued or outstanding as of June 30, 2024 and December 31, 2023 | ||||||||
| Class A Common Stock, $ par value, shares authorized, and shares issued and outstanding, respectively, as of June 30, 2024 and December 31, 2023 | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total FOXO’s stockholders’ deficit | ( | ) | ( | ) | ||||
| Noncontrolling interest | ( | ) | ||||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
| 1 |
Foxo Technologies INc. and subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share data)
(Unaudited)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net revenues | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Direct costs of revenues | ||||||||||||||||
| Research and development | ||||||||||||||||
| Management contingent share plan expense | ||||||||||||||||
| Impairment of intangible assets and cloud computing arrangements | ||||||||||||||||
| Selling, general and administrative expenses | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of warrant liability | ||||||||||||||||
| Loss from PIK Note Amendment and 2022 Debenture Release | ( | ) | ( | ) | ||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (expense) income | ( | ) | ( | ) | ||||||||||||
| Total non-operating expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Provision for income taxes | ||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Noncontrolling interest | ||||||||||||||||
| Net loss attributable to FOXO | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Deemed dividends related to the Exchange Offer and extension of and trigger of down round provisions of Assumed Warrants | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share of Class A common stock, basic and diluted | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| Weighted average shares of Class A common stock, basic and diluted (in thousands) | ||||||||||||||||
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
| 2 |
FOXO TECHNOLOGIES INC. and subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (EQUITY)
(Dollars in thousands)
(Unaudited)
| Class A Common | Additional | Total FOXO | Total Stockholders’ | |||||||||||||||||||||||||||||
| Stock | Treasury | Paid- | Accumulated | Stockholders’ | Noncontrolling | Equity | ||||||||||||||||||||||||||
| Shares | Amount | Stock | In-Capital | Deficit | Deficit | Interest | (Deficit) | |||||||||||||||||||||||||
| Balance, December 31, 2022 | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||
| Net loss to common stockholders | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Stock based compensation | ( | ) | ||||||||||||||||||||||||||||||
| Balance, March 31, 2023 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
| Net loss to common stockholders | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Stock based compensation | ( | ) | ||||||||||||||||||||||||||||||
| 2022 Debenture Release | ||||||||||||||||||||||||||||||||
| PIK Note Amendment | ||||||||||||||||||||||||||||||||
| Exchange Offer | ||||||||||||||||||||||||||||||||
| Treasury stock | ( | ) | ||||||||||||||||||||||||||||||
| Balance, June 30, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||
| 3 |
| Class A Common | Additional | Total FOXO | Total | |||||||||||||||||||||||||||||
| Stock | Treasury | Paid- | Accumulated | Stockholders’ | Noncontrolling | Stockholders’ | ||||||||||||||||||||||||||
| Shares | Amount | Stock | In-Capital | Deficit | Deficit | Interest | Deficit | |||||||||||||||||||||||||
| Balance, December 31, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||
| Net loss to common stockholders | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Stock-based compensation | ( | ) | ||||||||||||||||||||||||||||||
| Shares issued under KR8 Agreement | ||||||||||||||||||||||||||||||||
| Shares issued under Corporate Development and Advisory Agreement | ||||||||||||||||||||||||||||||||
| Shares issued to MSK under Shares for Services Agreement | ||||||||||||||||||||||||||||||||
| Shares issued to employee | ||||||||||||||||||||||||||||||||
| Warrants issuable for finder’s fees | - | |||||||||||||||||||||||||||||||
| Deemed dividends from trigger of down round provisions | ||||||||||||||||||||||||||||||||
| and extension of Assumed Warrants | - | |||||||||||||||||||||||||||||||
| Balance, March 31, 2024 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Noncontrolling interest | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Stock-based compensation | ( | ) | ||||||||||||||||||||||||||||||
| Shares issuable to IG under terms of note payable | - | |||||||||||||||||||||||||||||||
| Shares issued to LGH under terms of note payable | ||||||||||||||||||||||||||||||||
| Shares issued for legal settlement | ||||||||||||||||||||||||||||||||
| Warrants issuable for finder’s fees | - | |||||||||||||||||||||||||||||||
| Shares issuable for Myrtle acquisition | - | |||||||||||||||||||||||||||||||
| Shares issuable to institutional investors under terms of senior notes payable | - | |||||||||||||||||||||||||||||||
| Noncontrolling interest | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Deemed dividends from trigger of down round provisions of Assumed Warrant | - | |||||||||||||||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
| 4 |
FOXO TECHNOLOGIES INC. and subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
(Unaudited)
Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Loss from PIK Note Amendment and 2022 Debenture Release | ||||||||
| Stock-based compensation | ||||||||
| Amortization of consulting fees paid in common stock | ||||||||
| Impairment of intangible assets and cloud computing arrangements | ||||||||
| Loss on investment | ||||||||
| Change in fair value of warrants | ( | ) | ( | ) | ||||
| PIK Interest | ||||||||
| Legal settlement paid in common stock | ||||||||
| Amortization of debt discounts and issue costs | ||||||||
| Other | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Supplies | ||||||||
| Prepaid expenses | ||||||||
| Change in right-of-use lease asset | ( | ) | ||||||
| Other current assets | ||||||||
| Accounts payable, including related payable payables | ||||||||
| Accrued and other liabilities | ( | ) | ||||||
| Change in right-of-use lease liability | ||||||||
| Net cash provided by (used in) operating activities | ( | ) | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of Myrtle, net of cash acquired | ( | ) | ||||||
| Intangible asset acquired under license agreement | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from promissory note issued to RHI for acquisition of Myrtle | ||||||||
| Payment on note payable to RHI | ( | ) | ||||||
| Cash from issuances of promissory notes | ||||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
| 5 |
Foxo technologies inc. and subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in thousands, except per share data)
Note 1 DESCRIPTION OF BUSINESS
FOXO Technologies Inc. (“FOXO” or the “Company”), formerly known as Delwinds Insurance Acquisition Corp. (“Delwinds”), a Delaware corporation, was originally formed in April 2020 as a publicly traded special purpose company for the purpose of effecting a merger, capital stock exchange, asset acquisition, reorganization, or similar business combination involving one or more businesses. FOXO is commercializing epigenetic biomarker technology to support groundbreaking scientific research and disruptive next-generation business initiatives. The Company applies automated machine learning and artificial intelligence (“AI”) technologies to discover epigenetic biomarkers of human health, wellness and aging and, with the acquisition of Myrtle Recovery Centers, Inc. (“Myrtle”) effective on June 14, 2024, the Company offers behavioral health services, including substance abuse treatment. The acquisition of Myrtle is more fully discussed in Note 5.
Segments
The Company manages and classifies its business into two reportable business segments: (i) Healthcare; and (ii) Labs and Life. Previously, Labs and Life were treated as separate segments, however, with the acquisition of Myrtle, the Company’s operational focus shifted such that it was appropriate to combine its Labs and Life segments and to operate Myrtle under the Company’s newly formed Healthcare segment.
The Business Combination
On February 24, 2022, Delwinds entered into a definitive Agreement and Plan of Merger, dated as of February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022 (the “Merger Agreement”), with FOXO Technologies Inc., now known as FOXO Technologies Operating Company (“FOXO Technologies Operating Company”), DWIN Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Delwinds (“Merger Sub”), and DIAC Sponsor LLC (the “Sponsor”), in its capacity as the representative of the stockholders of Delwinds from and after the closing (the “Closing”) of the transactions contemplated by the FOXO Transaction Agreement (collectively, the “Transaction” or the “Business Combination”).
The Business Combination was approved by Delwinds’ stockholders on September 14, 2022, and closed on September 15, 2022 (the “Closing Date”) whereby Merger Sub merged into FOXO Technologies Operating Company, with FOXO Technologies Operating Company surviving the merger as a wholly owned subsidiary of the Company (the “Combined Company”), and with FOXO Technologies Operating Company security holders becoming security holders of the Combined Company. Immediately upon the Closing, the name of Delwinds was changed to FOXO Technologies Inc.
Following the Closing, FOXO became a holding company whose wholly-owned subsidiary, FOXO Technologies Operating Company, conducted all of the core business operations. FOXO Technologies Operating Company maintains its two wholly-owned subsidiaries, FOXO Labs Inc. and FOXO Life, LLC. FOXO Labs maintains a wholly-owned subsidiary, Scientific Testing Partners, LLC, while FOXO Life Insurance Company was a wholly-owned subsidiary of FOXO Life, LLC. On February 3, 2023, the Company sold FOXO Life Insurance Company as more fully discussed in Note 13. On June 14, 2024, FOXO acquired Myrtle as more fully discussed in Note 5.
Note 2 GOING CONCERN UNCERTAINTY AND MANAGEMENT’S PLAN
Under Accounting Standards Codification (“ASC”), Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirement of ASC 205-40.
| 6 |
The
Company’s history of losses requires management to critically assess its ability to continue operating as a going concern. For
the six months ended June 30, 2024, and 2023, the Company incurred net losses to common stockholders of $
The Company’s ability to continue as a going concern is dependent on generating revenue, raising additional equity or debt capital, reducing losses and improving future cash flows. The Company will continue ongoing capital raise initiatives and has demonstrated previous success in raising capital to support its operations, including the private placements and debt financings. However, the Company is unlikely to receive proceeds from the exercise of outstanding warrants as a result of the difference between the current trading price of the Company’s Common Stock and the exercise price of the warrants.
During the first quarter of 2023, we completed the sale of FOXO Life Insurance Company in order to gain access to the cash held as statutory capital and surplus at FOXO Life Insurance Company, which we used to fund a portion of our operations during 2023. To fund our operations, we continue to (i) pursue additional avenues to capitalize the Company, (ii) pursue the acquisitions of strategic operating companies, including Myrtle and Rennova Community Health, Inc. (“RCHI”), as more fully discussed in Note 5, and (iii) commercialize our products to generate revenue. See Note 9 for information on promissory notes payable issued during the six months ended June 30, 2024.
Compliance with NYSE American Continued Listing Requirements
On April 17, 2024, the Company received an official notice of noncompliance from the New York Stock Exchange (“NYSE”) stating that it was not in compliance with NYSE American continued listing standards due to the failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Delinquent Report”) by the filing due date of April 16, 2024 (the “Filing Delinquency”). With the filing of the Delinquent Report and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, the Filing Delinquency was cured.
On June 10, 2024, the Company received an official notice of noncompliance from NYSE stating that the Company is not in compliance with NYSE American continued listing standards due to an outstanding balance of listing fees over 180 days old and NYSE provided the Company until June 7, 2024 to provide payment before the Company would become subject to the noncompliance procedures. The Company failed to pay the fee by June 7, 2024, which was extended to August 9, 2024. On August 7, 2024, the Company received a letter from NYSE stating that the Company is back in compliance with the NYSE American continued listed standards pertaining to timely payment of listing fees set forth in Section 1003(f)(iv) of the NYSE American Company Guide. The letter acknowledged that the Company has paid its outstanding balance of fees.
On
July 10, 2024, the Company received an official notice of noncompliance from NYSE stating that the Company is not in compliance with
Section 1003(a)(ii) of the Company Guide since it reported stockholders’ deficit of ($
On
June 12, 2023, the Company received an official notice of noncompliance from NYSE Regulation stating that the Company is below compliance
with Section 1003(a)(i) in the NYSE American Company Guide since the Company reported stockholders’ deficit of $
| 7 |
Senior PIK Notes
As
previously disclosed, on September 20, 2022, the Company issued to certain investors
The Company can provide no assurance that these actions will be successful or that additional sources of financing will be available on favorable terms, if at all. As such, until additional equity or debt capital is secured and the Company begins generating sufficient revenue, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of these unaudited condensed consolidated financial statements. Assuming the Company is successful in closing the stock exchange agreement to acquire RCHI, which is more fully discussed in Note 5, the Company believes it will be able to fund its operations until December 31, 2024. In any event, if the Company is unable to fund its operations, it will be required to evaluate further alternatives, which could include further curtailing or suspending its operations, selling the Company, dissolving and liquidating its assets or seeking protection under the bankruptcy laws. A determination to take any of these actions could occur at a time that is earlier than when the Company would otherwise exhaust its cash resources.
The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Note 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting, and thus the accompanying unaudited condensed consolidated financial statements do not include all information and footnotes necessary for a complete presentation of financial position, results of operations or cash flows. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023 and the notes thereto. The consolidated balance sheet data as of December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments of a normal or recurring nature, which are necessary for a fair presentation of financial position, operating results and cash flows for the periods presented. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.
The unaudited condensed consolidated financial statements include the accounts of FOXO and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation.
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012, and it thus may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. For further information regarding the Company’s basis of presentation and use of estimates, refer to the audited consolidated financial statements as of and for the year ended December 31, 2023. The policies and estimates described in that report are used for preparing the Company’s quarterly unaudited condensed consolidated financial statements.
| 8 |
COMPREHENSIVE LOSS
During the three and six months ended June 30, 2024 and 2023, comprehensive loss was equal to the net loss amounts presented in the unaudited condensed consolidated statements of operations.
RECLASSIFICATIONS
Certain items in the 2023 financial statements have been reclassified for comparison purposes.
REVERSE STOCK SPLIT
On
October 31, 2023, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended, to implement a
The Company effected the Reverse Stock Split on November 6, 2023 at 4:01pm Eastern Time of its issued and outstanding shares of Class A Common Stock, which was previously approved by stockholders at the Company’s annual meeting of stockholders held on May 26, 2023 to regain compliance with Section 1003(f)(v) of the NYSE Company Guide.
Trading reopened on November 7, 2023, which is when the Company’s Class A Common Stock began trading on a post reverse stock split basis. All share information included in these unaudited condensed financial statements has been reflected as if the Reverse Stock Split occurred as of the earliest period presented.
REVENUE RECOGNITION POLICY
The Company recognizes revenue in accordance with ASC, “Revenue from Contracts with Customers (Topic 606),” including subsequently issued updates. The Company has recorded minor amounts of revenues from its Labs and Life segment during the three and six months ended June 30, 2024 and 2023. Presently, its healthcare segment consists of the operations of Myrtle. Myrtle’s revenues relate to contracts with patients in which its performance obligations are to provide behavioral health care services to its patients. Revenues are recorded during the period its obligations to provide health care services are satisfied. Myrtle’s performance obligations for inpatient services are generally satisfied over periods averaging approximately 7 to 28 days depending on the service line, and revenues are recognized based on charges incurred. The contractual relationships with patients, in most cases, also involve third-party payers and the transaction prices for the services provided are dependent upon the terms provided or negotiated with (the third-party payers. The payment arrangements with third-party payers for the services Myrtle provides to its patients typically specify payments at amounts less than its standard charges. Services provided to patients are generally paid at prospectively determined rates per diem. Management continually reviews the contractual estimation process to consider the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Under the revenue recognition accounting guidance, revenues are presented net of estimated contractual allowances and estimated implicit price concessions. Myrtle’s net revenues are based upon the estimated amounts it expects to be entitled to receive from third-party payers and patients based, in part, on Tennessee Medicaid rates. Myrtle also records estimated implicit price concessions related to uninsured accounts to record self-pay revenues at the estimated amounts it expects to collect.
The collection of outstanding receivables is Myrtle’s primary source of operating cash and is critical to its operating performance. The primary collection risks relate to patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Accounts are written off when all reasonable internal and external collection efforts have been carried out. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions and other collection indicators.
CONTRACTUAL ALLOWANCES AND DOUBTFUL ACCOUNTS POLICY
In accordance with ASC, “Revenue from Contracts with Customers (Topic 606),” including subsequently issued updates, the Company does not present “allowances for doubtful accounts” on its balance sheets, rather its accounts receivable are reported at realizable value, net of estimated contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts after all collection efforts have ceased or the account is settled for less than the amount originally estimated to be collected. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as adjustments to revenues.
| 9 |
During
the three and six months ended June 30, 2024, estimated contractual allowances of $
RECENTLY ISSUED ACCOUNTING STANDARDS
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires enhanced annual disclosures for specific categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective for public business entities for annual periods beginning on January 1, 2025. The Company plans to adopt ASU 2023-09 effective January 1, 2025 applying a retrospective approach to all prior periods presented in the financial statements. The Company does not believe the adoption of this new standard will have a material effect on its disclosures.
Other pronouncements issued by the FASB with future effective dates are either not applicable or are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.
The Company excluded the effect of and Management Contingent Shares outstanding and not vested as of June 30, 2024 and 2023, respectively, from the computation of basic net loss per share as the conditions to trigger the vesting of such shares had not been satisfied during the respective periods. Shares issued to the Company’s former CEO pursuant to the Management Contingent Share Plan, which are under review to determine if such shares should be forfeited in accordance with such plan are included in net loss per share. See Note 15 for additional information.
The Company excluded the effect of the Public Warrants, the Private Placement Warrants, the Assumed Options, and the Finder’s warrants from the computation of diluted net loss per share for the three and six months ended June 30, 2024 and 2023, as applicable, as their inclusion would have been anti-dilutive because the Company was in a loss position for such periods.
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net loss - basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Deemed dividend related to the Exchange Offer and the extension of and trigger of down round provisions of Assumed Warrants | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss to common stockholders - basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted weighted average number of Class A Common Stock | ||||||||||||||||
| Basic and diluted net loss per share available to Class A Common Stock | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
June 30, 2024 | June 30, 2023 | |||||||
| Public and private warrants | ||||||||
| Assumed Warrants | ||||||||
| Stock options | ||||||||
| Finder’s warrants | ||||||||
| Total antidilutive shares | ||||||||
| 10 |
Note 5 ACQUISITION AND STOCK EXCHANGE AGREEMENTS
On June 10, 2024, the Company entered into two stock exchange agreements, each with Rennova Health, Inc., a Delaware corporation, (“RHI”).
Acquisition of Myrtle Under First Stock Exchange Agreement
The
first agreement, as supplemented, (the “Myrtle Agreement”), provided for RHI to exchange all of its equity interest in Myrtle
for $
Myrtle was formed in the second quarter of 2022 to pursue opportunities in the behavioral health sector, including substance abuse treatment, initially in rural markets. Services are provided on either an inpatient, residential basis or an outpatient basis.
On August 10, 2023, Myrtle was granted a license by the Department of Mental Health and Substance Abuse Services of Tennessee to operate an alcohol and drug treatment facility in Oneida, Tennessee. The facility, which is located at RHI’s Big South Fork Medical Center campus, commenced operations and began accepting patients on August 14, 2023. The facility offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. On November 1, 2023, Myrtle began accepting patients at its Nonresidential Office-Based Opiate Treatment Facility (“OBOT”). The OBOT is located adjacent to Myrtle’s alcohol and drug treatment facility in Oneida, Tennessee and supplements the existing residential rehabilitation and detoxification services offered at Myrtle.
On
April 11, 2023, Myrtle sold shares of its common stock equivalent to a
The preliminary fair value of the purchase consideration payable to RHI under the terms of the Myrtle Agreement was allocated to the net tangible and intangible assets acquired. The Company accounted for the acquisition as a business combination under U.S. GAAP. In accordance with the acquisition method of accounting under ASC Topic 805, “Business Combinations,” (“ASC 805”) the assets acquired and liabilities assumed were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company.
The
Company will undertake a valuation study to determine the fair value of the assets acquired. The preliminary estimated fair value of
the assets acquired, and net of the liabilities assumed is approximately $
Management Agreement
On
June 1, 2024, Myrtle and RHI entered into a management agreement wherein RHI agreed to provide management and consulting services to
Myrtle for a management fee of $
| 11 |
Lease Agreement
Myrtle
entered into a formal lease agreement with RHI under which Myrtle agreed to lease facilities at RHI’s Big South Fork Medical Center
campus beginning on June 14, 2024 for a term of one year with annual options to renew for up to five additional years with an initial
monthly base rental amount of $
FOXO acquired Myrtle as a synergistic opportunity to expand its operations into the healthcare sector and as a compliment to its epigenetic biomarkers of human health, wellness and aging.
The following table shows the preliminary allocation of the purchase price of Myrtle to the acquired identifiable assets acquired, and liabilities transferred on June 14, 2024:
| Total purchase price | $ | |||
| Tangible and Intangible assets acquired, and liabilities assumed at estimated fair value: | ||||
| Cash | $ | |||
| Accounts receivable, net | ||||
| Property and equipment, net | ||||
| Right-of-use lease asset | ||||
| Accounts payable | ( | ) | ||
| Accrued expenses | ( | ) | ||
| Right-of-use lease liability | ( | ) | ||
| Note payable to RHI | ( | ) | ||
| Noncontrolling interest | ||||
| Assets acquired, net of liabilities transferred | $ | ( | ) | |
| Goodwill | $ |
The
total cost relating to the acquisition was approximately $
The following presents the unaudited pro-forma combined results of operations of the Company and Myrtle as if the acquisition had occurred on January 1, 2023.
| Three-Months Ended | Six-Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net Revenue | $ | $ | $ | $ | ||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Deemed dividend from trigger of down round provision feature | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted net loss to common stockholders | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| Weighted average number of common shares outstanding during the period: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2023 or to project potential operating results as of any future date or for any future periods.
| 12 |
Second Stock Exchange Agreement with RHI
In the second agreement with RHI (the “RCHI Agreement”), dated June 10, 2024, the Company agreed to issue shares of its to be designated Series A Cumulative Convertible Redeemable Preferred Stock (the “Preferred Stock”) to RHI in exchange for all of the outstanding shares of RHI’s subsidiary, Rennova Community Health, Inc. (“RCHI”). RCHI owns all of the outstanding shares of Scott County Community Hospital, Inc. (operating as Big South Fork Medical Center), RHI’s critical access care hospital in Oneida, Tennessee. Each share of the Company’s Preferred Stock will have a stated value of $. The number of shares of the Company’s Preferred Stock issuable to RHI upon the closing of the RCHI Agreement is subject to adjustment as provided in the RCHI Agreement.
The closing of the RCHI Agreement is subject to a number of conditions, including the approval of the shareholders of each of the Company and RHI.
Note 6 ACCOUNTS RECEIVABLE, NET
Accounts Receivable as of June 30, 2024 and December 31, 2023 were as follows:
June 30, 2024 | December 31, 2023 | |||||||
| Accounts receivable, gross | $ | $ | ||||||
| Less: | ||||||||
| Allowance for contractual obligations | ( | ) | ||||||
| Accounts receivable, net | $ | $ | ||||||
Note 7 PROPERTY AND EQUIPMENT, NET
Property and equipment, net as of June 30, 2024 and December 31, 2023 were as follows:
June 30, 2024 | December 31, 2023 | |||||||
| Leasehold improvements | $ | $ | ||||||
| Furniture and fixtures | ||||||||
| Computer equipment | ||||||||
| Software | ||||||||
| Medical equipment | ||||||||
| Less accumulated depreciation | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Property
and equipment are depreciated on a straight-line basis over their respective lives. Leasehold improvements are depreciated over the life
of the lease and the remaining equipment and software is being depreciated over lives ranging from one to ten years. Depreciation expense
on property and equipment was $
| 13 |
Note 8 INTANGIBLE ASSETS AND GOODWILL
Intangible assets as of June 30, 2024 and December 31, 2023 were as follows:
June 30, 2024 | December 31, 2023 | |||||||
| Methylation pipeline | $ | $ | ||||||
| Epigenetic APP | ||||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||
| Intangible assets, net | $ | $ | ||||||
Amortization
of the Company’s intangible assets is recorded on a straight-line basis within selling, general and administrative expenses over
three years. The Company recognized amortization expense of intangible assets of $
The Company’s Epigenetic APP intangible asset was acquired from KR8 under the terms of a license agreement, which is more fully discussed in Note 10.
Goodwill
Goodwill
was $
Note 9 NOTES PAYABLE
At June 30, 2024 and December 31, 2023 notes payable with third parties consisted of the following:
June 30, 2024 | December 31, 2023 | |||||||
| Senior PIK Notes in the principal amount of $ | $ | $ | ||||||
| ClearThink Notes in the aggregate principal amount of $ | ||||||||
| LGH Note Payable in the principal amount of $ | ||||||||
| IG Note Payable in the principal amount of $ | ||||||||
| Note payable to RHI in the principal amount of $ | ||||||||
| Note payable to RHI in principal amount of $ | ||||||||
| Senior Note Payable in the principal amount of $ | ||||||||
| Total third-party notes payable | ||||||||
| Less current portion of third-party notes payable | ( | ) | ( | ) | ||||
| Total third-party notes payable, net of current portion | $ | $ | ||||||
In
addition, as of June 30, 2024 and December 31, 2023, the Company had outstanding notes payable with related parties of $
15% Senior PIK Notes
On
September 20, 2022, the Company entered into separate Securities Purchase Agreements with accredited investors pursuant to which the
Company issued its Senior PIK Notes in the aggregate principal amount of $
| 14 |
The
Senior PIK Notes bear interest at
The Company had agreed to not obtain additional equity or debt financing, without the consent of a majority of the holders of the Senior PIK Notes, other than if a financing pays amounts owed on the Senior PIK Notes, with the exception of certain exempt issuances. The Company shall not incur other indebtedness, except for certain exempt indebtedness, until such time the Senior PIK Notes are repaid in full; however, the Senior PIK Notes are unsecured.
PIK Note Amendment
On
May 26, 2023, the Company consummated two issuer tender offers: (i) the Exchange Offer (as described in Note 9) and (ii) the Offer to
Amend
Pursuant
to the PIK Note Offer to Amend, the Company solicited approval from holders of Senior PIK Notes to amend the PIK Note Purchase Agreement
to permit the following issuances by the Company of its Class A Common Stock and Common Stock Equivalents (as defined in the PIK Note
Purchase Agreement), without prepaying the Senior PIK Notes: (i) the issuance of shares of the Company’s Class A Common Stock in
connection with the PIK Offer Note Offer to Amend, (ii) the issuance of shares of the Company’s Class A Common Stock in connection
with the Exchange Offer (as defined in Note 12), (iii) the issuance of shares of the Company’s Class A Common Stock or Common Stock
Equivalents (as defined in the PIK Note Purchase Agreement) in connection with the 2022 Bridge Debenture Release (defined in Note 12),
(iv) the issuance of shares of the Company’s Class A Common Stock or Common Stock Equivalents (as defined in the PIK Note Purchase
Agreement) in (a) a private placement of the Company’s equity, equity-linked or debt securities resulting in gross proceeds to
the Company no greater than $
The Company received consents from all Senior PIK Note holders and all required approvals, including stockholder approval, and issued on a pro rata basis to the holders of the Senior PIK Notes shares of its Class A Common Stock in consideration for the PIK Note Amendment.
The
Company accounted for the PIK Note Amendment as an extinguishment as the consideration of $
Pursuant
to the terms of the Senior PIK Notes, commencing on November 1, 2023, and on each one-month anniversary thereof, the Company is required
to pay the holders of the PIK Notes an equal amount until their outstanding principal balance has been paid in full on the Maturity Date,
or, if earlier, upon acceleration or prepayment of the Senior PIK Notes in accordance with their terms. The Company failed to make the
payments due on November 1, 2023 and on each one-month anniversary thereof, which constitutes an event of default under the Senior PIK
Notes. As a result of the event of default, the interest rate of the Senior PIK Notes increased from
| 15 |
Given the Company’s current cash constraints, as previously discussed in Note 2, the Company is currently in discussions with the holders of the Senior PIK Notes with respect to certain amendments to the Senior PIK Notes to cure the event of default; however, there can be no assurance that the Senior PIK Note holders will agree to amend the PIK Notes.
As
of June 30, 2024 and December 31, 2023, the Company has recorded the $
Notes Payable to ClearThink Capital Partners, LLC
During
the six months ended June 30, 2024, the Company issued three promissory notes to ClearThink Capital Partners, LLC (“ClearThink”).
On January 3, 2024, the Company issued ClearThink a promissory note in the principal amount of $
Funding
of the ClearThink Notes occurred on various dates during the period January 4, 2024 through June 20, 2024. During the six months ended
June 30, 2024, the Company received cash proceeds of $
Securities Purchase Agreement Dated April 28, 2024 With LGH Investments
On
April 28, 2024, the Company entered into a Securities Purchase Agreement with LGH Investments, LLC, a Wyoming limited liability company
(“LGH”), pursuant to which the Company issued to LGH a convertible, non-interest bearing promissory note in the principal
amount of $
| 16 |
Securities Purchase Agreement Dated April 30, 2024 With IG Holdings, Inc.
On
April 30, 2024, the Company entered into a Securities Purchase Agreement with IG Holdings, Inc., an Arizona corporation
(“IG”), pursuant to which the Company issued IG a promissory note in the principal amount of $
Finder’s Fee Agreement
Under
the terms of a Finder’s Fee Agreement dated October 9, 2023, the Company is obligated to pay the finder a cash fee equal to
Note Payable to RHI for the Acquisition of Myrtle
Pursuant
to the acquisition of Myrtle as more fully discussed in Note 5, the Company issued a non-interest bearing note payable to RHI in the
amount of $
Note Payable to RHI
Note payable to RHI dated June 13, 2024, in the original
principal amount of $
Securities Purchase Agreement with Institutional Investor Dated June 12, 2024
On
June 12, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”)
pursuant to which it agreed to issue to the Purchaser and subsequent purchasers who will also be parties to the SPA (the Purchaser, together
with the purchasers, the “Purchasers”) Senior Notes in the aggregate principal amount of up to $
The closings of the SPA (each a “Closing,” or, together, the “Closings”) are as follows:
| ● | On
the Initial Closing Date (as defined below), the Purchaser or Purchasers purchased $ | |
| ● | Upon
the filing of a preliminary proxy statement or information statement with the SEC relating to the approval by the Company’s
stockholders of an agreement by the Company to acquire the shares of common stock of RCHI from RHI, and all transactions contemplated
thereby (the “Acquisition”), the Purchasers will purchase up to an aggregate of $ | |
| ● | Upon
the closing of the Acquisition, the Purchasers will purchase up to an aggregate of $ | |
| ● | Upon
the filing of a registration statement by the Company with the SEC relating to the resale by the Purchasers (and any affiliates)
of all shares of the Company’s Class A Common Stock beneficially owned by each Purchaser (and any affiliate) the Purchasers
will purchase up to an aggregate of $ |
| 17 |
Each Closing is subject to additional conditions as disclosed in the SPA.
On
June 14, 2024 (the “Initial Closing Date”), pursuant to the SPA, the Company issued a Senior Note Payable in the
principal amount of $
The
Senior Note Payable provides the Purchaser with rights upon a Fundamental Transaction (as defined in the Senior Note Payable) such as
assumption rights of the Successor Entity (as defined in the Senior Note Payable). The Senior Note Payable also provides the Purchaser
an exchange right upon the issuance of preferred stock (except in connection with the Acquisition) and mandatory redemption rights. There
is also an optional prepayment of the Senior Note Payable provided to the Company of
The
Company recorded the $
Note 10 RELATED PARTY TRANSACTIONS
Consulting Agreement
In
April 2022, the Company executed a consulting agreement (the “Consulting Agreement”) with an individual (the “Consultant”)
considered to be a related party of the Company as a result of his investment in 2021 Bridge Debentures. The agreement, which expired
in April 2023, had a minimum term of twelve months, over which the Consultant was to provide services that included, but were not limited
to, advisory services relating to the implementation and completion of the Business Combination. The Company determined that all compensation
costs related to the Consulting Agreement, including both cash and equity fee paid in 2022, represented remuneration for services to
be rendered evenly over the contract term. Thus, all such costs were initially recorded at fair value as prepaid consulting fees in the
consolidated balance sheet and were being recognized as selling, general and administrative expenses in the unaudited condensed consolidated
statement of operations on a straight-line basis over the term of the contract. For the three and six months ended June 30, 2023, $
Sponsor Loan
In
order to finance transaction costs in connection with the Business Combination, the Sponsor or an affiliate of the Sponsor loaned Delwinds
funds for working capital. As of June 30, 2024 and December 31, 2023, $
Demand Promissory Notes
On
September 19, 2023, the Company obtained a $
On
October 2, 2023, the Company obtained a $
The promissory notes discussed above are shown as related parties payables and promissory notes on the unaudited condensed consolidated balance sheets.
| 18 |
Management, License and Maintenance Fees Under the KR8 Agreement
On October 29, 2023, the Company entered into a Letter Agreement with KR8 to develop a Direct-to-Consumer APP (iOS and Android) combining its AI Machine Learning technology to provide a commercial application of FOXO’s epigenetic biomarker technology as a subscription consumer engagement platform. Effective January 12, 2024, the Letter Agreement was replaced with the Master Software and Services Agreement between the Licensor and the Company (the “KR8 Agreement”). The Company’s Interim CEO and Interim CFO each are equity owners of the Licensor. Under the KR8 Agreement, the Licensor granted to the Company a limited, non-sublicensable, non-transferable perpetual license to use the “Licensor Products,” which are listed in Exhibit A to the KR8 Agreement, to develop, launch and maintain license applications based upon the Company’s epigenetic biomarker technology and software to develop an AI machine learning Epigenetic APP to enhance health, wellness and longevity. The territory of the KR8 Agreement is solely within the U.S., Canada and Mexico.
Under
the KR8 Agreement, the Company agreed to pay to the Licensor an initial license and development fee of $
The initial term of the KR8 Agreement commences on the effective date of the KR8 Agreement. Unless terminated earlier in accordance with the terms, the KR8 Agreement will be perpetual. Either party may terminate the KR8 Agreement, effective on written notice to the other party, if the other party materially breaches the KR8 Agreement, and such breach remains uncured 30 days after the non-breaching party provides the breaching party with written notice of such breach, in which event, the non-breaching party will then deliver a second written notice to the breaching party terminating the KR8 Agreement, in which event the KR8 Agreement, and the licenses granted under the KR8 Agreement, will terminate on the date specified in such second notice. Either party may terminate the KR8 Agreement, effective immediately upon written notice to the other party, if the other party: (i) is unable to pay, or fails to pay, its debts as they become due; (ii) becomes insolvent, files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law; (iii) makes or seeks to make a general assignment for the benefit of its creditors; or (iv) applies for or has appointed a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.
The Company may terminate the Agreement at any time upon 90 days’ notice to the Licensor provided that, as a condition to such termination, the Company immediately ceases using any Licensor Products. The Licensor may terminate the KR8 Agreement at any time upon 30 days’ notice to the Company if the Company fails to pay any portion of the “Initial License Fee,” as defined in the KR8 Agreement.
Under
the terms of the KR8 Agreement, on January 19, 2024, during the six months ended June 30, 2024, the Company issued shares of
its Class A Common Stock to the Licensor valued at $
Interim CEO Service Agreement
As more fully discussed in Note 17, on July 25, 2024, FOXO entered into a new agreement with the Company’s Interim CEO that superseded his previous interim management fee arrangement.
| 19 |
Note 11 RIGHT-OF-USE LEASE ASSET AND LIABILITY
As discussed in Note 5, FOXO leases facilities for its Myrtle operations under an operating lease with RHI. For operating leases with terms greater than 12 months, including annual options that are expected to be renewed, FOXO records the related right-of-use asset and right-of-use lease liability at the present value of lease payments over the term. FOXO does not separate lease and non-lease components of contracts.
FOXO uses an estimated borrowing interest rate at lease commencement as its interest rate, as its operating lease does not provide a readily determinable implicit interest rate.
The following table presents FOXO’s lease-related asset and liability at June 30, 2024 and December 31, 2023:
| Balance Sheet Classification | June 30, 2024 | December 31, 2023 | ||||||||
| Assets: | ||||||||||
| Operating lease | Right-of-use operating lease asset | $ | $ | |||||||
| Liabilities: | ||||||||||
| Current: | ||||||||||
| Operating lease | Right-of-use operating lease liability | $ | $ | |||||||
| Noncurrent: | ||||||||||
| Operating lease | Right-of-use operating lease liability | |||||||||
| Total right-of-use lease liability | $ | $ | ||||||||
| Remaining term of operating lease, including option periods expected to renew | n/a | |||||||||
| Interest rate | % | n/a | ||||||||
The following table presents certain information related to lease expense for the right-of-use operating lease for the three and six months ended June 30, 2024 and 2023:
| Three-Months Ended | Six-Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Right-of-use operating lease amortization (1) | $ | $ | $ | $ | ||||||||||||
| Right-of-use operating lease interest expense (2) | ||||||||||||||||
| 20 |
The following table presents supplemental cash flow information for the six months ended June 30, 2024 and 2023:
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|||||||
| Operating cash flows for right-of-use operating lease | $ | $ | ||||||
| (1) | |
| (2) |
Aggregate future minimum lease payments under the right-of-use operating lease are as follows:
Right-of-Use Operating Lease | ||||
| Twelve months ending: | ||||
| July 1, 2024 to June 30, 2025 | $ | |||
| July 1, 2025 to June 30, 2026 | ||||
| July 1, 2026 to June 30, 2027 | ||||
| July 1, 2027 to June 30, 2028 | ||||
July 1, 2028 to June 30, 2029 | ||||
| Thereafter | ||||
| Total | ||||
| Less interest | ( | ) | ||
| Present value of minimum lease payments | ||||
| Less current portion of right-of-use lease liability | ( | ) | ||
| Right-of-use lease liability, net of current portion | $ | |||
Note 12 STOCKHOLDERS’ (DEFICIT) EQUITY
The Company’s authorized shares of all capital stock, par value $ per share, of shares, consisting of (i) shares of preferred stock and (ii) shares of Class A Common Stock.
Preferred Stock
The Amended and Restated Certificate of Incorporation authorizes the Company to issue shares of preferred stock with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2024 and December 31, 2023, there were shares of preferred stock issued or outstanding.
Class A Common Stock
As of June 30, 2024 and December 31, 2023, there were and shares of the Company’s Class A Common Stock issued and outstanding, respectively.
Common Stock Issued to KR8 under KR8 Agreement
On January 19, 2024, the Company issued shares of its Class A Common Stock pursuant to the KR8 Agreement, which is more fully discussed in Note 10.
| 21 |
February 1, 2024 Second Strata Purchase Agreement
On
February 1, 2024, the Company entered into a Second Strata Purchase Agreement (the “Second Strata Purchase Agreement”) with
ClearThink. Pursuant to the Second Strata Purchase Agreement, after the satisfaction of certain commencement conditions, including, without
limitation, the effectiveness of the Registration Statement (as defined below), ClearThink has agreed to purchase from the Company, from
time to time upon delivery by the Company to ClearThink of request notices (each a “Request Notice”), and subject to the
other terms and conditions set forth in the Second Strata Purchase Agreement, up to an aggregate of $
Each
purchase under the Second Strata Purchase Agreement will be in a minimum amount of $
As of June 30, 2024, shares of the Company’s common stock were issued under the Second Strata Purchase Agreement.
Finder’s Fee Agreement
On
October 9, 2023, the Company entered into the Finder Agreement, by and between the Company and the Finder. Pursuant to a Finder Agreement
the Company will pay the Finder a cash fee equal to
Common Stock Issued to MSK Under Shares for Services Agreement
On September 19, 2023, the Company entered into a Shares for Services Agreement with MSK pursuant to which the Company issued to MSK in September 2023 shares of Company’s Class A Common Stock valued at $ and rights (the “Rights”) to receive shares of the Company’s Class A Common Stock valued at $ in satisfaction of outstanding amounts payable to MSK in an aggregate amount equal to $ for legal services rendered. During the six months ended June 30, 2024, the Company issued to MSK shares of its Class A Common Stock in full satisfaction of the Rights.
Common Stock Issued to Tysadco Partners under Corporate Development Advisory Agreement
On March 5, 2024, the Company issued shares of its Class A Common Stock to Tysadco Partners under the Corporate Development Advisory Agreement dated effective February 26, 2024. Under the agreement, Tysadco Partners will provide strategic, financing, capital structure and other guidance and expertise to the Company’s management.
| 22 |
Common Stock Issued to LGH
In April 2024, the Company issued shares of its Class A Common Stock to LGH in connection with the LGH Note Payable as more fully discussed in Note 9.
In June 2024, the Company issued shares of its Class A Common Stock in connection with a legal settlement, which is more fully discussed in Note 15 under the heading, “Smithline Family Trust II vs. FOXO Technologies Inc. and Jon Sabes.”)
Warrants
Public Warrants and Private Placement Warrants
The
Company has outstanding
Finders Warrants
Pursuant
to the terms of the Finder’s Agreement, which is more fully discussed above, and in connection with a private placement of the
Company’s Class A Common Stock to ClearThink during the three months ended December 31, 2023, which is more fully discussed in
Note 7 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December
31, 2023, the Company issued or is obligated to issue to the Finder
In
addition, in connection with the issuances of the ClearThink Notes, the LGH Note Payable and IG Note Payable, which are more fully discussed
in Note 9, the Company is obligated to issue
Assumed Warrants
At
Closing of the Business Combination, the Company assumed common stock warrants that were exchanged for common stock warrants to purchase
On
February 23, 2024,
| 23 |
Exchange Offer
On
May 26, 2023, the Company consummated its tender offer commenced on April 27, 2023, to all
Bridge Debenture Release
The Company entered into two separate general release agreements in June of 2023 (the “General Release Agreements” and such transaction, the “2022 Bridge Debenture Release”). The General Release Agreements are with former registered holders (the “Investors”) of 10% Original Issue Discount Convertible Debentures issued in 2022 by Legacy FOXO (the “2022 Bridge Debentures”).
Pursuant
to their respective General Release Agreement, each Investor released, waived and discharged the Company from any and all claims that
such Investor had, have or may have against the Company from the beginning of time through the effective date of their respective General
Release Agreement (the “Release”). As consideration for the Release and each Investor’s other obligations, covenants,
agreements, representations and warranties set forth in their respective General Release Agreement, the Company issued to each Investor
shares of Class A Common Stock for every $
The
Company issued shares to the Investors in exchange for the release and recognized expense of $
Treasury Stock
On April 14, 2023, the Company cancelled the shares of treasury stock that it held.
Note 13 FOXO LIFE INSURANCE COMPANY
On
February 3, 2023, the Company consummated the sale of FOXO Life Insurance Company to Security National Life Insurance Company (the “Buyer”).
At closing, all of the FOXO Life Insurance Company’s shares were cancelled and retired and ceased to exist in exchange for the
assignment to the Company of FOXO Life Insurance Company’s statutory capital and surplus amount of $
Note 14 BUSINESS SEGMENTS
During the three and six months ended June 30, 2024 and 2023, the Company managed and classified its business into two reportable business segments: (i) Healthcare and (ii) Labs and Life
| ● | Healthcare - The Company’s healthcare segment began with the acquisition of Myrtle on June 14, 2024, as more fully discussed in Note 5. Healthcare offers behavioral health services, including substance abuse treatment. Services are provided on either an inpatient, residential basis or an outpatient basis. Presently, it offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. | |
| ● | Labs and Life - The Company’s Labs and Life segment is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the global life insurance industry. The Company’s innovative biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. The Company’s research demonstrates that epigenetic biomarkers, collected from saliva, provide measures of individual health and wellness for the factors used in life insurance underwriting traditionally obtained through blood and urine specimens. On February 3, 2023, the Company sold FOXO Life Insurance Company as more fully discussed in Note 13. |
| 24 |
The primary income measure used for assessing segment performance and making operating decisions is income (losses) before interest, income taxes, depreciation, amortization, and stock-based compensation. The segment measure of profitability also excludes corporate and other costs, including management, IT, overhead costs and certain other non-cash charges or benefits, such as impairment and any non-cash changes in fair value.
Healthcare generates revenues from the substance abuse treatments, including inpatient and outpatient services. Labs and Life generates revenues through performing epigenetic biomarker services and by collecting epigenetic services royalties and residual revenues from the sale of life insurance products.
With the acquisition of Myrtle on June 14, 2024, the Chief Operating Decision Maker (“CODM”) has begun to use asset information to make decisions and allocate resources. Asset by segment as of June 30, 2024 and December 31, 2023 were as follows:
June 30, 2024 | December 31, 2023 | |||||||
| Healthcare | $ | $ | ||||||
| Labs and Life | ||||||||
| Corporate and other | ||||||||
| Total assets | $ | $ | ||||||
Summarized below is information about the Company’s operations for the three months ended June 30, 2024 and 2023 by business segment:
| Revenues | Losses | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Healthcare | $ | $ | $ | ( | ) | $ | ||||||||||
| Labs and Life | ( | ) | ( | ) | ||||||||||||
| ( | ) | ( | ) | |||||||||||||
| Impairments of intangible assets | - | - | ( | ) | ||||||||||||
| 2022 Debenture Release and PIK Note Amendment | - | - | ( | ) | ||||||||||||
| Corporate and other (a) | ( | ) | ( | ) | ||||||||||||
| Interest expense | - | - | ( | ) | ( | ) | ||||||||||
| Total | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||
| (a) |
Summarized below is information about the Company’s operations for the six months ended June 30, 2024 and 2023 by business segment:
| Revenues | Losses | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Healthcare | $ | $ | $ | ( | ) | $ | ||||||||||
| Labs and Life | ( | ) | ( | ) | ||||||||||||
| ( | ) | ( | ) | |||||||||||||
| Impairments of intangible assets | - | - | ( | ) | ||||||||||||
| 2022 Debenture Release and PIK Note Amendment | - | - | ( | ) | ||||||||||||
| Corporate and other (a) | ( | ) | ( | ) | ||||||||||||
| Interest expense | - | - | ( | ) | ( | ) | ||||||||||
| Total | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||
| (a) |
| 25 |
Note 15 COMMITMENTS AND CONTINGENCIES
The Company is a party to various vendor and license agreements and sponsored research arrangements in the normal course of business that create commitments and contractual obligations.
As more fully discussed in Note 10, effective January 12, 2024, the Company entered into the KR8 Agreement. The Company’s Interim CEO and Interim CFO each are equity owners of KR8. See Note 17 for agreements entered into subsequent to June 30, 2024.
Legal Proceedings
The
Company accrues for costs associated with certain contingencies, including, but not limited to, settlement of legal proceedings, regulatory
compliance matters and self-insurance exposures when such costs are probable and reasonably estimable. In addition, the Company records
legal fees in defense of asserted litigation and regulatory matters as such legal fees are incurred. To the extent it is probable that
the Company is able to recover losses and legal fees related to contingencies, it records such recoveries concurrently with the accrual
of the related loss or legal fees. Significant management judgment is required to estimate the amounts of such contingent liabilities.
In the Company’s determination of the probability and ability to estimate contingent liabilities, it considers the following: litigation
exposure based on currently available information, consultations with external legal counsel and other pertinent facts and circumstances
regarding the contingency. Liabilities established to provide for contingencies are adjusted as further information develops, circumstances
change, or contingencies are resolved; and such changes are recorded in the condensed consolidated statements of operations during the
period of the change and appropriately reflected in the condensed consolidated balance sheets. At June 30, 2024 and December 31, 2023,
the Company had $
Smithline Family Trust II vs. FOXO Technologies Inc. and Jon Sabes
On
November 18, 2022, Smithline filed a complaint against the Company and Jon Sabes, the Company’s former Chief Executive Officer
and a former member of the Company’s board of directors, in the Supreme Court of the State of New York, County of New York, Index
0654430/2022. The complaint asserted claims for breach of contract, unjust enrichment and fraud, alleging that (i) the Company breached
its obligations to Smithline pursuant to that certain Securities Purchase Agreement, dated January 25, 2021, between Legacy FOXO and
Smithline, the 2021 Bridge Debentures, due February 23, 2022, and Assumed Warrant to purchase shares of FOXO common stock until February
23, 2024 (collectively, including any amendment or other document entered into in connection therewith, the “Financing Documents”),
(ii) the Company and Mr. Sabes were unjustly enriched as a result of their alleged actions and omissions in connection with the Financing
Documents, and (iii) the Company and Mr. Sabes made materially false statements or omitted material information in connection with the
Financing Documents. The complaint claims damages in excess of a minimum of $
On December 23, 2022, the Company removed this action from the Supreme Court of the State of New York, County of New York to the United States District Court for the Southern District of New York, Case 1:22-cv-10858-VEC. The action was assigned to Judge Valerie E. Caproni.
On February 1, 2023, Defendant Jon Sabes moved to dismiss the Complaint as to Defendant Sabes pursuant to Fed. R. Civ. P. 12(b)(2) and 12(b)(6).
On February 22, 2023, Smithline filed an Amended Complaint. The Company filed its Answer to the Amended Complaint on March 8, 2023.
| 26 |
On March 15, 2023, Defendant Jon Sabes moved to dismiss the Amended Complaint as to Defendant Sabes pursuant to Fed. R. Civ. P. 12(b)(1), (2) & (6).
On April 17, 2023, Smithline filed its opposition to Defendant Sabes’ motion.
On November 7, 2023, Smithline and the Company and its subsidiaries entered into the Settlement Agreement, pursuant to which the parties agreed to resolve and settle all disputes and potential claims which exist or may exist among them, including without limitation those claims asserted in the Action, as more specifically set forth in, and subject to the terms and conditions of, the Settlement Agreement. Upon the execution of the Settlement Agreement, the parties agreed to jointly dismiss the action without prejudice.
Pursuant
to the Settlement Agreement, the Company agreed to pay Smithline the “Cash Settlement Payment,” payable in full no later
than the date that is the 12-month anniversary of the effective date of the Settlement Agreement (such date, the “Settlement Deadline”
and, such period, the “Settlement Period”). During the Settlement Period, the Company agreed to pay Smithline out of any
Equity Financing a minimum of
In
addition, the Company agreed to use commercially reasonable efforts to pay $
In
addition, the parties agreed that prior to Smithline receiving $
In
addition, the parties agreed that after Smithline has received $
Pursuant to the Settlement Agreement, the Company agreed to use its best efforts to obtain an amendment to its Senior PIK Notes such that their maturity date and amortization dates are extended to December 31, 2024. Whether such amendment is obtained or not, the Company agreed to not make any payments in cash or stock on such Senior PIK Notes or permit such Senior PIK Notes to convert into stock prior to the satisfaction in full of the Cash Settlement Payment.
Simultaneous with the execution of the Settlement Agreement, Smithline and Puritan Partners LLC and the Company entered into a mutual release (the “Mutual Release”), which will be held in escrow pending notification from counsel for Smithline that 90 calendar days have elapsed since Smithline has received the Cash Settlement Payment in full. The Mutual Release includes the release of, in addition to the Company, Jon Sabes, Bespoke Growth Partners, Inc. and Mark Peikin, subject to their satisfaction of the conditions of the Mutual Release, including delivery of an executed release to counsel for Smithline releasing the Claiming Parties (as defined in the Mutual Release). Pursuant to the Mutual Release, in the event that the Company files for bankruptcy and the Claiming Parties are not permitted to retain the Cash Settlement Payment or the net proceeds received on the sale of Settlement Shares, if any, the Mutual Release will be null and void and void ab initio. Further, in the event that Jon Sabes, Bespoke Growth Partners, Inc., or Mark Peikin commences a lawsuit or arbitration or otherwise asserts a claim or cause of action against any of the Responding Parties (as defined in the Mutual Release) or any of the Claiming Parties, or takes any action against or otherwise hinders in any manner the Company’s ability to repay the Claiming Parties the Cash Settlement Payment or deliver and register the Settlement Shares, if any, the release of such person or entity will be null and void and void ab initio.
| 27 |
Pursuant
to the Settlement Agreement, without the prior written consent of Smithline, the Company may not (x) pay KR8, including its affiliates,
in cash more than the sum of (A) (i) $ a month for the first three months after the effective date of the Settlement Agreement and
(ii) more than $ a month for months 4 to 12 after the effective date of the Settlement Agreement and (B) a royalty for
Pursuant
to the Settlement Agreement, the parties agreed that Smithline may retain the Smithline Assumed Warrant issued to Smithline pursuant
to the Agreement and Plan of Merger, dated February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022, by and
among the Company (DWIN Merger Sub Inc., DIAC Sponsor LLC, and Legacy FOXO; provided, however, that the Smithline Assumed Warrant will
be automatically cancelled immediately upon Smithline’s receipt of the Cash Settlement Payment in full. Further, due to the fact
that the Company did not pay the Cash Settlement Payment in full prior to the warrant’s expiration on February 23, 2024, the Smithline
Assumed Warrant was automatically extended for a year until February 23, 2025, subject to cancellation upon Smithline’s receipt
of the Cash Settlement Payment. From the effective date of the Settlement Agreement until the Settlement Deadline, Smithline may not
exercise any of its rights under the Smithline Assumed Warrant so long as the Company continues to comply with the Settlement Agreement.
In the event the Company or any of its subsidiaries is subject to a Bankruptcy Event (as defined in the Debenture) then immediately prior
to the occurrence of such Bankruptcy Event, the Smithline Assumed Warrant will be converted into an unsecured debt obligation of the
Company and its subsidiaries in the amount of $
Exchange Agreement with Smithline Dated May 28, 2024
On
May 28, 2024, the Company, entered into an Exchange Agreement with Smithline pursuant to which Smithline exchanged the Smithline Assumed
Warrant to purchase up to shares, as adjusted, of the Company’s Common Stock terminating on February 23, 2025, for the
right to receive up to shares of the Company’s Class A Common Stock (the “Rights Shares”), subject to a
The Company is currently in default of the Settlement Agreement and is currently in negotiations with Smithline on a resolution.
Former CEO Severance
As of June 30, 2024, the Board has yet to complete its review into whether the former CEO was terminated with or without cause. Accordingly, the Company has yet to make a determination on its obligations under the former CEO’s employment agreement. The Company has accrued for his severance and has recognized expenses related to his equity-based compensation per the terms of his contract while the matter remains under review.
Should
the review conclude that the former CEO was terminated without cause then the former CEO will receive thirty-six months of severance
based on his base salary, his options granted immediately vest, and his Management Contingent Share Plan related to performance-based
conditions that have been met become fully vested. As of June 30, 2024 and December 31, 2023, $
Should the review conclude the former CEO was terminated with cause then no severance or continued benefits are due and the Company will account for the forfeiture of his Management Contingent Share Plan and reverse the accrual and corresponding expense related to his severance.
Additionally, the Company cancelled the Management Contingent Share Plan related to performance-based conditions that have not been met.
| 28 |
Disputed Severance Policy
A
severance policy was drafted in early 2023 with an effective date of January 9, 2023. The policy applied to all exempt level vice presidents
and above employees across various departments. It provided for a six-month salary pay out if the employee, while in good standing, was
involuntarily separated from the Company. However, neither the Company’s board of directors nor its remuneration committee approved
the policy. If the policy were valid, five former employees would have met the guidelines to receive the severance aggregating approximately
$
Three former employees have sent letters, through their attorneys, requesting the payment of the severance. The Company has responded to the letters stating that the policy was not valid and that all of the Company’s obligations related to their separation from the Company have been paid and/or fully satisfied.
SEC Investigation
On March 3, 2023, the Company received a document request from the SEC indicating that the SEC was conducting an investigation regarding the Company and sought documents concerning (1) Jon Sabes’ termination as CEO, (2) Jon Sabes’ resignation from the Company’s board of directors, and (3) Steven Sabes’ termination as COO, and is voluntarily responding to the SEC’s request. According to the SEC’s request, its investigation does not mean that the SEC has concluded that anyone violated the law or that the SEC has a negative opinion of the Company or any person, event, or security.
On July 9, 2024, the Company received a letter from the SEC has concluded the investigation and, based on the information it had as of that date, it does not intend to recommend an enforcement action against the Company.
The Company is also party to various other legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business, and the Company may in the future be subject to additional legal proceedings and disputes.
Note 16 SUPPLEMENTAL DISCLOSRE OF CASH FLOW INFORMATION
The supplemental cash flow information for the six months ended June 30, 2024 and 2023 is as follows:
| Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Non-cash investing and financing activities: | ||||||||
| 2022 Debenture Release | $ | $ | ||||||
| PIK Note Amendment | $ | $ | ||||||
| Deemed dividends from Exchange Offer | $ | $ | ||||||
| Deemed dividends from trigger of down round provisions and extension of Assumed Warrants | $ | $ | ||||||
| Class A Common Stock issued/issuable as inducements in debt financings | $ | $ | ||||||
| Warrants issuable for finder’s fees | $ | $ | ||||||
| Class A Common Stock issuable for Myrtle acquisition | $ | $ | ||||||
| 29 |
Note 17 SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued in this 10-Q. Other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the accompanying unaudited condensed consolidated financial statements.
Class A Common Stock Issued to RHI for Equity Interest in Myrtle
In connection with the acquisition of Myrtle, which is more fully discussed in Note 5, on July 17, 2024, the Company issued to RHI shares of its Class A Common Stock.
Class A Common Stock Issued to Purchaser Under SPA
On July 17, 2024, the Company issued the Purchaser shares of its Class A Common Stock in connection with the Senior Note Payable, which is more fully discussed in Note 9.
Corporate Development Advisory Agreement Commencing July 17, 2024
On July 25, 2024, the board of directors of the Company approved FOXO entering into the Corporate Development Advisory Agreement with C L Talent Inc. (“C. L. Talent”), (the “Talent Agreement”). Pursuant to the Talent Agreement, commencing July 17, 2024, the C. L. Talent will reasonably be available during regular business hours to advise, counsel and inform designated officers and employees of FOXO about the health, wellness and social media businesses in which the Company is engaged, competitors, business opportunities, talent engagement and other aspects of or concerning FOXO’s business about which C. L. Talent has knowledge or expertise. In addition, it will assist FOXO with targeting key talent with whom FOXO has an existing relationship to further enhance market reach. The term of the Talent Agreement is 12 months. As compensation for services to be provided under the Talent Agreement, FOXO will issue to C. L. Talent shares of the Company’s Class A Common Stock pending approval from the NYSE.
Financial Adviser
On July 25, 2024, FOXO entered into the advisory agreement with J.H. Darbie & Co., Inc. (“J.H. Darbie”) pursuant to which J.H. Darbie was engaged as nonexclusive financial adviser. The term of the agreement is six months. As compensation for the services to be performed under the agreement, the Company is obligated to issue to J.H. Darbie shares of its Class A Common Stock.
Private Placement Engagement
On
July 25, 2024, FOXO engaged J.H. Darbie, on an exclusive basis, to provide services in connection with private placements (the “Engagement”).
The term of the Engagement is 120 days, subject to early termination provisions in the Engagement. Under the Engagement, J.H. Darbie
has a right of first refusal for all financing, cash, common stock or convertible securities, debt or equity, for six months after the
termination of the Engagement. As compensation for the services to be performed under the Engagement, the Company will pay a nonrefundable
fee of $
As
additional compensation for the services to be rendered by J.H. Darbie under the Engagement, FOXO will (i) pay a cash fee to J.H. Darbie
equal to
Services Agreement With Interim CEO
On
July 25, 2024, FOXO entered into a new Services Agreement with Mark White that superseded the interim employment agreement (the “Services
Agreement”). The initial term of the Services Agreement is until July 31, 2026. Pursuant to the Services Agreement, Mr. White
is entitled to monthly fees of $
| 30 |
FOXO may terminate the Services Agreement at any time without Cause (as defined in the Services Agreement), provided that the Company give written notice of termination at 60 days before the date of such termination. In which case, Mr. White is be entitled to receive the following:
(i) payment of 24 months’ of monthly fees which, may be taken in cash or common stock of FOXO at Mr. White’s sole option; and (ii) reimbursement for any outstanding reasonable business expenses incurred by Mr. White in performing his duties.
The Company may terminate the Services Agreement at any time for Cause, provided that the Company gives written notice of termination to Mr. White. If the Services Agreement is terminated for Cause, Mr. White is entitled to:
(i) accrued and unpaid monthly fees through the date of such termination; and (ii) reimbursement for any outstanding reasonable business expenses incurred by Mr. White in performing his duties.
The Services Agreement will terminate upon a Change of Control (as defined in the Services Agreement). If the Services Agreement is terminated upon Change of Control, Mr. White will be entitled to:
(i) payment of 24 months of monthly fees which, may be taken in cash or common stock of the Company at Mr. White’s sole option; and (ii) reimbursement for any outstanding reasonable business expenses incurred by Mr. White in performing his duties.
For purposes of the Services Agreement, a termination for “Change of Control” means: (i) A change in control of the Company of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A as in effect on the date of this Agreement pursuant to the Exchange Act; provided that, without limitation, such a change in control will be deemed to have occurred at such time as any Acquiring Person hereafter becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 30% or more of the combined voting power of Voting Securities; or (ii) during any period of 12 consecutive calendar months, individuals who at the beginning of such period constitute the Board of Directors cease for any reason to constitute at least a majority thereof unless the election, or the nomination for election, by the Company’s stockholders of each new director was approved by a vote of at least a majority of the directors then in office who were directors at the beginning of the period; or (iii) there will be consummated (1) any acquisition by the Company of stock or assets of another entity actively engaged in business, in connection with which the Company issues Voting Securities or any security, instrument or agreement exercisable for or convertible into Voting Securities, representing in the aggregate more than 100% of the Voting Securities outstanding prior to the entry into an agreement to consummate such acquisition, notwithstanding that the exercise or conversion of such security, instrument or agreement is subject to a vote of the shareholders of the Company, (2) any consolidation or merger of the Company in which the Company is not the continuing or surviving corporation or pursuant to which Voting Securities would be converted into cash, securities, or other property, other than a merger of the Company in which the holders of Voting Securities immediately prior to the merger have the same proportionate ownership of common stock of the surviving corporation immediately after the merger, or (3) any sale, lease, exchange, or other transfer (in one transaction or a series of related transactions) of all, or substantially all, of the assets of the Company; or (iv) approval by the stockholders of the Company of any plan or proposal for the liquidation or dissolution of the Company.
For purposes of the Services Agreement, “Acquiring Person” means any person or related person or related persons which constitute a “group” for purposes of Section 13(d) and Rule 13d-5 under the Exchange Act, as such Section and Rule are in effect as of the date of this Agreement; provided, however, that the term Acquiring Person shall not include (i) the Company or any of its subsidiaries, (ii) any employee benefit plan of the Company or any of its subsidiaries, (iii) any entity holding voting capital stock of the Company for or pursuant to the terms of any such employee benefit plan, or (iv) any person or group solely because such person or group has voting power with respect to capital stock of the Company arising from a revocable proxy or consent given in response to a public proxy or consent solicitation made pursuant to the Exchange Act.
For purposes of the Services Agreement, “Voting Securities” means the Company’s issued and outstanding securities ordinarily having the right to vote at elections for director.
Upon the termination of the Services Agreement, upon the payment of all obligations owing to Mr. White by the Company, unless the Company will otherwise request, Mr. White shall resign from all positions within the Company.
| 31 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
References to the “Company,” “FOXO,” “us,” “our” or “we” refer to FOXO Technologies Inc. and its consolidated subsidiaries. The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, capital resources and cash flows of our Company as of and for the periods presented below. You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed consolidated financial statements and the related notes included elsewhere in this Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. In addition to our historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future. Dollar amounts are in thousands, except per share amounts or unless otherwise noted.
Overview
FOXO is focused on commercializing scientific discoveries in health and longevity. A pivotal moment in the field of longevity science came with the discovery that epigenetics could be used to develop measures of health, including biological aging, according to an article published in the scientific journal, Nature, in 2014. In recent years, we and other scientists have extended these findings to assess tobacco, alcohol, blood cell composition, and other health measures based on discovered epigenetic biomarkers. To that end, FOXO is dedicated to research and development in order to provide data-driven insights based on the numerous health measures that can be determined through this unique dimension of biology and used to foster optimal health and longevity for both individuals and organizations. We believe there is value in what these biomarkers will be able to provide to the world. Current testing options can be inaccurate, piecemeal, and often require obtaining a blood sample. Epigenetic biomarkers may pave the path for a fully comprehensive, at-home, low-cost test that could, with other existing testing, offer a much easier, more detailed sense of one’s health.
At the same time, we believe there exists a significant bottleneck in scientific research and product development using epigenetic data. Due to the complexity of the data, many scientists are unaware of how to properly process such data or take full advantage of the available tools. With our experience in bringing to market new tools (both software and hardware) and know-how (our Bioinformatics Services and analytic consulting), we believe we are well-positioned to help reduce barriers in advancing epigenetic research and the development of epigenetic-based products. Thus, we have chosen strategically to extend our expertise in epigenetic data processing and analysis to outside parties in an effort to further accelerate new discoveries. This work not only allows us to generate revenue, but also continue our work in developing improved ways in processing and analyzing this important data.
Historically, we have had two core product offerings related to the commercialization of epigenetic science: the “Underwriting Report,” and the “Longevity Report™.” The Underwriting Report, which has been under development and is currently paused until we increase our cash resources in order to continue additional research and development, is intended to allow us to leverage a single assay testing process to generate a panel of impairment scores that could be applied by life insurance underwriters to more efficiently assess clients during the underwriting process and provide a more personalized risk assessment. The Longevity Report, sales of which have also been paused as we redevelop and re-strategize around this product, was designed as a customer-facing consumer engagement product that provides actionable insights based on one’s biological age and other epigenetic measures of health and wellness.
Historically, we were operationalizing a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with longevity-promoting products such as our Longevity Report. We previously marketed and sold life insurance products underwritten and issued by third-party carriers through distribution relationships (the “MGA Model”). The MGA Model allowed us to appoint sales agents and producers to sell insurance products for specific carriers and earn commissions on subsequent policy sales. On October 2, 2023, we decided to pause sales of new life insurance products and move existing producers out of the MGA Model hierarchy to further conserve cash resources and focus resources on FOXO Labs.
| 32 |
Management, License and Maintenance Fees Under the KR8 Agreement
On October 29, 2023, we entered into a Letter Agreement with KR8 to develop a Direct-to-Consumer APP (iOS and Android) combining its artificial intelligence (“AI”) Machine Learning technology to provide a commercial application of our epigenetic biomarker technology as a subscription consumer engagement platform. Effective January 12, 2024, the Letter Agreement was replaced by the KR8 Agreement. Our Interim CEO and Interim CFO each are equity owners of the Licensor. Under the KR8 Agreement, the Licensor granted to us a limited, non-sublicensable, non-transferable perpetual license to use the Licensor’s products to develop, launch and maintain license applications based upon our epigenetic biomarker technology and software to develop an AI machine learning epigenetic APP to enhance health, wellness and longevity. The territory of the agreement is solely within the U.S., Canada and Mexico.
Recent Developments
Stock Exchange Agreements Dated June 10, 2024
On June 10, 2024, we entered into two stock exchange agreements, each with RHI.
The first agreement, as supplemented, (the “Myrtle Agreement”), provided for RHI to exchange all of its equity interest in Myrtle for $500, payable in a combination of shares of our Class A Common Stock and a note payable. The closing occurred on June 14, 2024. The purchase price payable for the equity interest in Myrtle will be subject to certain post-closing adjustments, as provided in the Myrtle Agreement.
Myrtle was formed in the second quarter of 2022 to pursue opportunities in the behavioral health sector, including substance abuse treatment. initially in rural markets. Services are provided on either an inpatient, residential basis or an outpatient basis.
On August 10, 2023, Myrtle was granted a license by the Department of Mental Health and Substance Abuse Services of Tennessee to operate an alcohol and drug treatment facility in Oneida, Tennessee. The facility, which is located at RHI’s Big South Fork Medical Center campus, commenced operations and began accepting patients on August 14, 2023. The facility offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. On November 1, 2023, Myrtle began accepting patients at its Nonresidential Office-Based Opiate Treatment Facility (“OBOT”). The OBOT is located adjacent to Myrtle’s alcohol and drug treatment facility in Oneida, Tennessee and supplements the existing residential rehabilitation and detoxification services offered at Myrtle.
The Company acquired Myrtle as a synergistic opportunity to expand its operations into the healthcare sector and as a compliment to its epigenetic biomarkers of human health, wellness and aging.
In the second agreement, the RCHI Agreement, we agreed to issue the Preferred Stock to RHI in exchange for all of the outstanding shares of RCHI. RCHI owns all of the outstanding shares of Scott County Community Hospital, Inc. (operating as Big South Fork Medical Center), RHI’s critical access care hospital in Oneida, Tennessee. Each share of our Preferred Stock will have a stated value of $1,000. The number of shares of our Preferred Stock issuable to RHI upon the closing of the RCHI Agreement is subject to adjustment as provided in the RCHI Agreement.
The closing of the RCHI Agreement is subject to a number of conditions, including the approval of the shareholders of each of us and RHI.
Also see Note 17 of the accompanying unaudited condensed financial statements for other recent developments.
| 33 |
Segments
We manage and classify our business into two reportable business segments: (i) Healthcare; and (ii) Labs and Life. Previously, Labs and Life were treated as separate segments, however, with the acquisition of Myrtle, our operational focus shifted such that it was appropriate to combine our Labs and Life segments and to operate Myrtle under our newly formed Healthcare segment.
| ● | Healthcare - The Company’s healthcare segment began with the acquisition of Myrtle on June 14, 2024, as more fully discussed in Note 5 to the accompanying unaudited condensed financial statements. Healthcare offers behavioral health services, including substance abuse treatment. Services are provided on either an inpatient, residential basis or an outpatient basis. Presently, it offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. | |
| ● | Labs and Life- Our Labs and Life segment is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the global life insurance industry. Our research demonstrates that epigenetic biomarkers, collected from saliva or blood, provide meaningful measures of health and lifestyle factors. Labs and Life anticipates recognizing revenue related to sales of its Bioinformatics Services and from the commercialization of research and development activities, which may include its Underwriting Report, Longevity Report, or as a result of other commercialization opportunities including a potential AI platform for the delivery of health and well-being data-driven insights to individuals, healthcare professionals and third-party service providers. Life sought to redefine the relationship between consumers and insurers by combining life insurance with healthy longevity. The distribution of insurance products that may be paired with our FOXO’s Longevity Report strived to provide life insurance consumers with valuable information and insights about their individual health and wellness. |
Labs currently recognizes revenue from providing epigenetic testing services and collecting a royalty from Illumina, Inc. related to the sales of the Infinium Mouse Methylation Array. Labs conducts research and development, and such costs are recorded within research and development expenses on the unaudited condensed consolidated statements of operations. Labs had operated its Bioinformatics Services as an ancillary offering, with revenue recognized as epigenetic biomarker services in our historical financial statements, but now looks to it as a primary offering. Bioinformatics Services provide a data processing, quality checking, and data analysis service using FOXO’s cloud-based bioinformatics pipeline, referred to as our epigenetics, longevity, or methylation pipeline in our historical financial statements. Labs accepts raw data from third party labs and converts that data into usable values for customers. Life primarily had residual commission revenues from its legacy insurance agency business. Life also began receiving insurance commissions from the distribution and sale of life insurance policies based on the size and type of policies sold to customers. Life costs are recorded within selling, general and administrative expenses on the consolidated statements of operations.
FOXO Life Insurance Company
Due to market conditions, our capitalization following the Business Combination did not materialize in the way the Company anticipated, and we did not possess the funding that we believed would be required to satisfy state regulations and regulatory bodies to issue new life insurance policies through FOXO Life Insurance Company. As such, we decided to not move forward with the launch of FOXO Life Insurance Company.
On February 3, 2023, we consummated the sale of FOXO Life Insurance Company to Security National pursuant to the Security National Merger Agreement. As a result of the merger, we were no longer required to hold cash and cash equivalents required to be held as statutory capital and surplus, as required under the Arkansas Insurance Code (the “Arkansas Code”).
At the closing, all of FOXO Life Insurance’s shares were cancelled and retired and ceased to exist in exchange of an amount equal to FOXO Life Insurance’s statutory capital and surplus amount of $5,002 as of the closing date, minus $200 (the “Merger Consideration”).
After the Merger Consideration and Security National’s third-party expenses, the transaction resulted in the Company gaining access to $4,751 that was previously held as statutory capital and surplus pursuant to the Arkansas Code.
| 34 |
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with U.S. GAAP, management periodically uses certain “non-GAAP financial measures,” as such term is defined under the rules of the SEC, to clarify and enhance understanding of past performance and prospects for the future. Generally, a non-GAAP financial measure is a numerical measure of a company’s operating performance, financial position or cash flows that excludes or includes amounts that are included in or excluded from the most directly comparable measure calculated and presented in accordance with U.S. GAAP. For example, non-GAAP measures may exclude the impact of certain items such as acquisitions, divestitures, gains, losses and impairments, or items outside of management’s control. Management believes that the following non-GAAP financial measure provides investors and analysts useful insight into our financial position and operating performance. Any non-GAAP measure provided should be viewed in addition to, and not as an alternative to, the most directly comparable measure determined in accordance with U.S. GAAP. Further, the calculation of these non-GAAP financial measures may differ from the calculation of similarly titled financial measures presented by other companies and therefore may not be comparable among companies.
Adjusted EBITDA provides additional insight into our underlying, ongoing operating performance and facilitates period-to-period comparisons by excluding the earnings impact of interest, tax, depreciation and amortization, non-cash change in fair value of convertible debentures and warrants, stock-based compensation, and impairment. Management believes that presenting Adjusted EBITDA is more representative of our operational performance and may be more useful for investors. Adjusted EBITDA along with a reconciliation to net loss is shown in Other Operating Data within the Results of Operations below.
Results of Operations
Three Months Ended June 30, 2024 and 2023
| Change in | Change in | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | $ | % | ||||||||||||
| Net revenues | $ | 28 | $ | 12 | $ | 16 | 133 | % | ||||||||
| Operating expenses: | ||||||||||||||||
| Direct costs of revenues | 31 | - | 31 | 100 | % | |||||||||||
| Research and development | 104 | 333 | (229 | ) | -69 | % | ||||||||||
| Management contingent share plan | 8 | 648 | (640 | ) | -99 | % | ||||||||||
| Impairment of intangible assets and | ||||||||||||||||
| cloud computing arrangements | - | 2,633 | (2,633 | ) | -100 | % | ||||||||||
| Selling, general and administrative | 1,474 | 4,003 | (2,529 | ) | -63 | % | ||||||||||
| Total operating expenses | 1,617 | 7,617 | (6,000 | ) | -79 | % | ||||||||||
| Loss from operations | (1,589 | ) | (7,605 | ) | 6,016 | -79 | % | |||||||||
| Non-operating expenses | (575 | ) | (3,688 | ) | 3,113 | -84 | % | |||||||||
| Net loss | (2,164 | ) | (11,293 | ) | 9,129 | -81 | % | |||||||||
| Noncontrolling interest | 1 | - | 1 | 100 | % | |||||||||||
| Net loss attributable to FOXO | (2,163 | ) | (11,293 | ) | 9,130 | -81 | % | |||||||||
| Deemed dividends | (310 | ) | (2,466 | ) | 2,156 | -87 | % | |||||||||
| Net loss to common stockholders | $ | (2,473 | ) | $ | (13,759 | ) | $ | 11,286 | -82 | % | ||||||
Net Revenues. Total revenues were $28 for the three months ended June 30, 2024, compared to $12 for the three months ended June 30, 2023. Myrtle, acquired on June 14, 2024, contributed $20 of the increase, partially offset by the decreases in FOXO Labs and FOXO Life revenues of $4.
Direct Costs of Revenues. Direct costs of revenues were $31 for the three months ended June 30, 2024, compared to no direct costs of revenues for the three months ended June 30, 2023. The increase resulted from the acquisition of Myrtle on June 14, 2024.
| 35 |
Research and Development. Research and development expenses were $104 for the three months ended June 30, 2024, compared to $333 for the three months ended June 30, 2023. The decrease was driven by lower employee-related expenses and professional services as well as research and development projects that are no longer ongoing, which also contributed to the period over period decrease in research and development expenses.
Management Contingent Share Plan. Management Contingent Share Plan expenses were $8 for the three months ended June 30, 2024 compared to expense of $648 for the three months ended June 30, 2023. The decrease was due to more shares vesting under the plan during the 2023 period.
Impairment of Intangible Assets and Cloud Computing Arrangements. During the three months ended June 30, 2023, we determined that the cash flows would no longer support the digital insurance platform, underwriting API, and longevity API and recognized impairment losses of $1,425, $630, and $578, respectively or $2,633 in total.
Selling, General and Administrative. Selling, general and administrative expenses were $1,474 for the three months ended June 30, 2024 compared to $4,003 for the three months ended June 30, 2023. The decrease of $2,529, or 63%, was driven by the completion of a consulting agreement as we recognized $519 less compensation costs associated with the amortization of consulting agreements in the current period compared to the prior period. Also contributing to the decrease were lower: employee related expenses due to headcount reductions, legal fees, amortization of intangible assets and professional fees, among other items. Partially offsetting the decrease in selling, general and administrative expenses were expenses of $37 associated with Myrtle, which was acquired on June 14, 2024.
Non-operating Expense. Non-operating expense was $575 for the three months ended June 30, 2024, compared to $3,688 for the three months ended June 30, 2023. The decrease is primarily related to the loss from PIK Note Amendment and 2022 Debenture Release of $3,521 during the three months ended June 30, 2023.
Net Loss. Net loss was $2,164 for the three months ended June 30, 2024, an improvement of $9,129 or 81% compared to net loss of $11,293 for the three months ended June 30, 2023. The decrease in net loss was primarily related to the decrease in the loss from operations of $6,016, and the decrease in other non-operating expenses of $3,113. Additionally, a deemed dividend of $310 related to the trigger of the down round provisions of the Smithline Assumed Warrants was recognized in the three months ended June 30, 2024 compared to a deemed dividend of $2,466 related to the Exchange Offer during the three months ended June 30, 2023. The deemed dividends resulted in net loss to common stockholders of $2,473 and $13,759 for the three months ended June 30, 2024 and 2023, respectively.
Analysis of Segment Results:
The following is an analysis of our results by reportable segment for the three months ended June 30, 2024 compared to the three months ended June 30, 2024. The primary earnings/loss measure used for assessing reportable segment performance is earnings/loss before interest, income taxes, depreciation, amortization, and stock-based compensation. Segment income/loss by reportable segment also excludes corporate and other costs, including management, IT, and overhead costs. For further information regarding our reportable business segments, please refer to our unaudited condensed consolidated financial statements and related notes included elsewhere in this report.
Healthcare
| (Dollars in thousands) | 2024 | 2023 | Change in $ | Change in % | ||||||||||||
| Net revenues | $ | 20 | $ | - | $ | 20 | 100 | % | ||||||||
| Operating expenses | (68 | ) | - | (68 | ) | 100 | % | |||||||||
| Less noncontrolling interest | 1 | - | 1 | 100 | % | |||||||||||
| Segment losses | $ | (67 | ) | $ | - | $ | (67 | ) | 100 | % | ||||||
Net revenues. Net revenues were $20 or the three months ended June 30, 2024 and represent the net revenue of Myrtle, which was acquired on June 14, 2024. Our healthcare segment began with the acquisition of Myrtle.
Segment Losses. Segment losses were $67 for the three months ended June 2024 and represent the losses of Myrtle, which was acquired on June 14, 2024.
| 36 |
Life and Labs
| (Dollars in thousands) | 2024 | 2023 | Change in $ | Change in % | ||||||||||||
| Net revenues | $ | 8 | $ | 12 | $ | (4 | ) | (33 | )% | |||||||
| Operating expenses | (511 | ) | (569 | ) | 58 | (11 | )% | |||||||||
| Segment losses | $ | (503 | ) | $ | (557 | ) | $ | 54 | (10 | )% | ||||||
Net revenues. Net revenues were $8 for the three months ended June 30, 2024 compared to $12 for the three months ended June 30, 2023. The decrease was due to lower royalty revenue and reduced life insurance commissions earned as we ceased placing policies from our legacy agency business.
Segment Losses. Segment losses decreased from $557 for the three months ended June 30, 2023 to $503 for the three months ended June 30, 2024. The decrease was driven by lower employee-related expenses, partially offset by minimum royalties due under the KR8 Agreement.
Six Months Ended June 30, 2024 and 2023
| Change in | Change in | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | $ | % | ||||||||||||
| Net revenues | $ | 35 | $ | 25 | $ | 10 | 40 | % | ||||||||
| Operating expenses: | ||||||||||||||||
| Direct costs of revenues | 31 | - | 31 | 100 | % | |||||||||||
| Research and development | 269 | 642 | (373 | ) | -58 | % | ||||||||||
| Management contingent share plan | 41 | 1,412 | (1,371 | ) | -97 | % | ||||||||||
| Impairment of intangible assets and cloud computing arrangements | - | 2,633 | (2,633 | ) | -100 | % | ||||||||||
| Selling, general and administrative | 2,462 | 10,335 | (7,873 | ) | -76 | % | ||||||||||
| Total operating expenses | 2,803 | 15,022 | (12,219 | ) | -81 | % | ||||||||||
| Loss from operations | (2,768 | ) | (14,997 | ) | 12,229 | -82 | % | |||||||||
| Non-operating expenses | (900 | ) | (3,935 | ) | 3,035 | -77 | % | |||||||||
| Net loss | (3,668 | ) | (18,932 | ) | 15,264 | -81 | % | |||||||||
| Noncontrolling interest | 1 | - | 1 | 100 | % | |||||||||||
| Net loss attributable to FOXO | (3,667 | ) | (18,932 | ) | 15,265 | -81 | % | |||||||||
| Deemed dividends | (966 | ) | (2,466 | ) | 1,500 | -61 | % | |||||||||
| Net loss to common stockholders | $ | (4,633 | ) | $ | (21,398 | ) | $ | 16,765 | -78 | % | ||||||
Net revenues. Net revenues were $35 for the six months ended June 30, 2024, compared to $25 for the six months ended June 30, 2023. Myrtle, acquired on June 14,2024, contributed $20 of the increase, partially offset by decreases in FOXO Labs and FOXO Life revenues of $10.
Direct Costs of Revenues. Direct costs of revenues were $31 for the six months ended June 30, 2024, compared to no direct costs of revenues for the six months ended June 30, 2023. The increase resulted from the acquisition of Myrtle on June 14, 2024.
Research and Development. Research and development expenses were $269 for the six months ended June 30, 2024, compared to $642 for the six months ended June 30, 2023. The decrease was driven by lower employee-related expenses and professional services as well as research and development projects that are no longer ongoing, which also contributed to the period over period decrease in research and development expenses.
Management Contingent Share Plan. Management Contingent Share Plan expenses were $41 for the six months ended June 30, 2024 compared to expense of $1,412 for the six months ended June 30, 2023. The decrease was due to more shares vesting under the plan during the 2023 period.
Impairment of Intangible Assets and Cloud Computing Arrangements. During the six months ended June 30, 2023, we determined that the cash flows would no longer support the digital insurance platform, underwriting API, and longevity API and recognized impairment losses of $1,425, $630, and $578, respectively or $2,633 in total.
| 37 |
Selling, General and Administrative. Selling, general and administrative expenses were $2,462 for the six months ended June 30, 2024 compared to $10,335 for the six months ended June 30, 2023. The decrease of $7,873, or 76%, was driven by the completion of a consulting agreement as we recognized $2,575 less compensation costs associated with the amortization of consulting agreements in the current period compared to the prior period. Also contributing to the decrease were lower: employee related expenses due to headcount reductions, legal fees, amortization of intangible assets and professional fees, among other items. Partially offsetting the decrease in selling, general and administrative expenses were expenses of $37 associated with Myrtle, which was acquired on June 14, 2024.
Non-operating Expense. Non-operating expense was $900 for the six months ended June 30, 2024, compared to $3,935 for the six months ended June 30, 2023. The decrease is primarily related to the loss from PIK Note Amendment and 2022 Debenture Release $3,521 during the six months ended June 30, 2023.
Net Loss. was $3,668 for the six months ended June 30, 2024, an improvement of $15,264 or 81% compared to net loss of $18,932 for the six months ended June 30, 2023. The decrease in net loss was primarily related to the decrease in the loss from operations of $12,229, and the decrease in other non-operating expenses of $3,035. Additionally, a deemed dividend of $966 related to the trigger of the down round provisions and the extension of the Smithline Assumed Warrants was recognized in the six months ended June 30, 2024 compared to a deemed dividend of $2,466 related to the Exchange Offer during the six months ended June 30, 2023. The deemed dividends resulted in net loss to common stockholders of $4,633 and $21,398 for the six months ended June 30, 2024 and 2023, respectively.
Analysis of Segment Results:
The following is an analysis of our results by reportable segment for the six months ended June 30, 2024 compared to the three and six months ended June 30, 2023. The primary earnings/loss measure used for assessing reportable segment performance is earnings/loss before interest, income taxes, depreciation, amortization, and stock-based compensation. Segment income/loss by reportable segment also excludes corporate and other costs, including management, IT, and overhead costs. For further information regarding our reportable business segments, please refer to our unaudited condensed consolidated financial statements and related notes included elsewhere in this report.
Healthcare
| (Dollars in thousands) | 2024 | 2023 | Change in $ | Change in % | ||||||||||||
| Net revenues | $ | 20 | $ | - | $ | 20 | 100 | % | ||||||||
| Operating expenses | (68 | ) | - | (68 | ) | 100 | % | |||||||||
| Less noncontrolling interest | 1 | - | 1 | 100 | % | |||||||||||
| Segment losses | $ | (67 | ) | $ | - | $ | (67 | ) | 100 | % | ||||||
Net revenues. Net revenues were $20 or the six months ended June 30, 2024 and represent the net revenue of Myrtle, which was acquired on June 14, 2024. Our healthcare segment began with the acquisition of Myrtle.
Segment Losses. Segment losses were $67 for the six months ended June 30, 2024 and represent the losses of Myrtle, which was acquired on June 14, 2024.
Labs and Life
| (Dollars in thousands) | 2024 | 2023 | Change in $ | Change in % | ||||||||||||
| Net revenues | $ | 15 | $ | 25 | $ | (10 | ) | (40 | )% | |||||||
| Operating expenses | (885 | ) | (1,519 | ) | (634 | ) | (42 | )% | ||||||||
| Segment losses | $ | (870 | ) | $ | (1,494 | ) | $ | (624 | ) | (42 | )% | |||||
Net revenues. Net revenues were $15 for the six months ended June 30, 2024 compared to $25 for the six months ended June 30, 2023. The decrease was due to lower royalty revenue and reduced life insurance commissions earned as we ceased placing policies from our legacy agency business.
Segment Losses. Segment losses decreased from $1,494 for the six months ended June 30, 2023 to $870 for the six months ended June 30, 2024. The decrease was driven by lower employee-related expenses and a $251 loss on the sale of FOXO Life Insurance Company in the six months ended June 30, 2023, partially offset by minimum royalties due under the KR8 Agreement.
| 38 |
Other Operating Data:
We use Adjusted EBITDA to evaluate our operating performance. Adjusted EBITDA does not represent and should not be considered an alternative to net income as determined by U.S. GAAP, and our calculations thereof may not be comparable to those reported by other companies. We believe Adjusted EBITDA is an important measure of operating performance and provides useful information to investors because it highlights trends in our business that may not otherwise be apparent when relying solely on U.S. GAAP measures and because it eliminates items that have less bearing on our operating performance. Adjusted EBITDA, as presented herein, is a supplemental measure of our performance that is not required by, or presented in accordance with, U.S. GAAP. We use non-GAAP financial measures as supplements to our U.S. GAAP results in order to provide a more complete understanding of the factors and trends affecting our business. Adjusted EBITDA is a measure of operating performance that is not defined by U.S. GAAP and should not be considered a substitute for net (loss) income as determined in accordance with U.S. GAAP.
| We | reconcile our non-GAAP financial measure to our net loss, which is its most directly comparable financial measure calculated and presented in accordance with U.S. GAAP. Our management uses Adjusted EBITDA as a financial measure to evaluate the profitability and efficiency of our business model. Adjusted EBITDA is not presented in accordance with U.S. GAAP. Adjusted EBITDA includes adjustments for provision for income taxes, as applicable, interest income and expense, depreciation and amortization, stock-based compensation, and certain other infrequent and/or unpredictable non-cash charges or benefits. |
For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net loss | $ | (2,163 | ) | $ | (11,293 | ) | $ | (3,667 | ) | $ | (18,932 | ) | ||||
| Add: Depreciation and amortization | 262 | 247 | 522 | 1,176 | ||||||||||||
| Add: Interest expense | 542 | 492 | 843 | 717 | ||||||||||||
| Add: Stock-based compensation | 144 | 1,268 | 288 | 3,894 | ||||||||||||
| Add: Change in fair value of warrant liability | - | (208 | ) | (8 | ) | (208 | ) | |||||||||
| Add: Impairments of intangible assets and cloud computing arrangements | - | 2,633 | - | 2,633 | ||||||||||||
| Add: Loss from PIK Note Amendment and 2022 Debenture Release | - | 3,521 | - | 3,521 | ||||||||||||
| Adjusted EBITDA | $ | (1,215 | ) | $ | (3,340 | ) | $ | (2,022 | ) | $ | (7,199 | ) | ||||
Liquidity and Capital Resources
Sources of Liquidity and Capital
We had cash and cash equivalents of $33 and $38 as of June 30, 2024 and December 31, 2023, respectively. We have incurred net losses since our inception. For the six months ended June 30, 2024 and 2023, we incurred net losses available to common stockholders of $4,633 and $21,398, respectively. At June 30, 2024, had a working capital deficit and a total stockholders’ deficit of $20,817 and $16,167, respectively. While cash of $551 was provided by operating activities for the six months ended June 30, 2024, our operations used cash of $5,300 for the six months ended June 30, 2023. We have generated limited revenue to date and expect to incur losses from our existing business in future periods.
Our current revenue is not adequate to fund our operations in the next twelve months and requires us to fund our business through other avenues until the time we achieve adequate scale. Securing additional capital is necessary to execute on our business strategy.
| 39 |
Financing
We have financed our business through a combination of equity and debt. During the third quarter of 2022, we entered into separate securities purchase agreements pursuant to which we issued our Senior PIK Notes in the aggregate principal of $3,458. We received net proceeds of $2,918, after deducting fees and expenses of $540.
During the third quarter of 2023, we completed two tranches of private placements that provided gross proceeds of $450 and $294. After deducting placement agent fees and other offering expenses, the net proceeds from the private placements were $260 and $217.
During the fourth quarter of 2024, we entered into a Strata Purchase Agreement (the “Strata Purchase Agreement”) with ClearThink, as supplemented by that certain Supplement to Strata Purchase Agreement, dated as of October 13, 2023, by and between us and ClearThink. During the fourth quarter of 2023, we completed two tranches of private placements under the terms of the Strata Purchase Agreement with ClearThink that provided gross proceeds of $200 and $256. After deducting finder’s fees and other offering expenses, the net proceeds from the private placements were of $186 and $246.
During the first quarter of 2024, we entered into a Second Strata Purchase Agreement with ClearThink wherein, and subject to certain limitations, including the effectiveness of a registration statement as defined in the agreement, ClearThink has agreed to purchase from us, from time to time an aggregate of $5,000 shares of our Class A Common Stock.
On January3, 2024, we issued to ClearThink a promissory note in the principal amount of $75, less an original issue discount of $25, on January 30, 2024, we issued to ClearThink a promissory note in the principal amount of up to $750, less an original issue discount of $250 and on May 15, 2024, we issued ClearThink a promissory note in the principal amount of $300, less an original issue discount of $100. We receive net proceeds totaling $658 during the six months ended June 30, 2024 from the issuances of the notes payable. We are in negotiations to extend the maturity date of the May 15, 2024 promissory note.
On April 28, 2024, we entered into a Securities Purchase Agreement with LGH pursuant to which we issued to LGH a convertible promissory note in the principal amount of $110 and 200,000 shares of our Class A Common Stock as inducement shares to LGH. We received cash of $100 from the issuance of the convertible promissory note.
On April 30, 2024, we entered into a Securities Purchase Agreement with IG pursuant to which we issued IG a promissory note in the principal amount of $150 and we agreed to issue 100,000 shares of our Class A Common Stock as inducement shares to IG. We received cash of $100 from the issuance of the promissory note. We are in negotiations to extend the maturity date.
Pursuant to the acquisition of Myrtle, a note payable to RHI due on December 31, 2024 in the amount of $1,611 was transferred to us and we issued a non-interest bearing note payable due on demand to RHI in the amount of $265 for a portion of the purchase price of Myrtle.
On June 12, 2024, we entered into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Purchaser”) pursuant to which we agreed to issue to the Purchaser and subsequent purchasers who will also be parties to the SPA (the Purchaser, together with the purchasers, the “Purchasers”) Senior Notes Payable in the aggregate principal amount of up to $2,800.
The closings of the SPA (each a “Closing,” or, together, the “Closings”) are as follows:
| ● | On the June 14, 2024, the Purchaser purchased an aggregate of $840 in principal amount of the Senior Note Payable and we received cash proceeds of $750. |
| ● | Upon the filing of a preliminary proxy statement or information statement with the SEC relating to the approval by our stockholders of an agreement by us to acquire the shares of common stock of RCHI from RHI, and all transactions contemplated thereby (the “Acquisition”), the Purchasers will purchase up to an aggregate of $280 in principal amount of the Senior Notes Payable. |
| ● | Upon the closing of the Acquisition, the Purchasers will purchase up to an aggregate of $1,120 in principal amount of the Senior Notes Payable. |
| ● | Upon the filing of a registration statement by us with the SEC relating to the resale by the Purchasers (and any affiliates) of all shares of Class A Common Stock of the Company beneficially owned by each Purchaser (and any affiliate) the Purchasers will purchase up to an aggregate of $560 in principal amount of the Senior Notes Payable. |
On June 14, 2024, we issued the Senior Note Payable in the principal amount of $840 to the Purchaser and we received cash of $750. On July 17, 2024, we issued to the Purchaser 1,108,755 shares of our common stock per the terms of the agreement.
| 40 |
Going Concern
Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses to support the growth of our business until we finalize the acquisition of RCHI. Capital expenditures have historically not been material to our consolidated operations, and we do not anticipate making material capital expenditures in 2024 or beyond. We expect that our liquidity requirements will continue to consist of working capital, including payments of outstanding debt and accrued liabilities and general corporate expenses associated with the growth of our business. Based on our current operations, we do not have sufficient capital to fund our operations for at least 12 months from the date hereof. We expect to address our liquidity needs through the pursuit of additional funding through a combination of equity or debt financings and strategic acquisitions to enable us to fund our operations.
We have taken various actions to bolster our cash position, including raising funds through the private placements and transactions with ClearThink, LGH and the Purchaser described above and conserving cash by issuing shares of our Class A Common Stock under license agreements, legal settlements, consulting agreements, finder’s fees related to equity and debt financing and consulting agreements, among other transactions. As more fully discussed above under “Recent Developments,” on June 10, 2024, we entered into two stock exchange agreements, each with RHI. Under the RCHI Agreement, we intend to acquire Big South Fork Medical Center, RHI’s critical care hospital, which we hope and anticipate will provide us with positive operating cash flows, although there can be no assurance that we will close the transaction or that it will provide us with positive cash flows.
Based on our current operating plan, our cash position as of June 30, 2024, and after taking into account the actions described above, we expect to be able to fund our operations through December 31, 2024. Even if our current operating plan is successful, we expect to need additional financing or other increase in our cash and cash equivalents balance to enable us to fund our future operations.
We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We may raise additional capital through equity offerings, debt financings or other capital sources. If we do raise additional capital through public or private equity offerings, or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely impact our existing stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take certain actions.
Cash Flows
Sox Months Ended June 30, 2024 and 2023
The following table summarizes our cash flow data for the six months ended June 30, 2024 and 2023 (dollars in thousands):
| Cash Provided by / (Used in) | ||||||||
| Three Months Ended June 30, | 2024 | 2023 | ||||||
| Operating Activities | $ | 551 | $ | (5,300 | ) | |||
| Investing Activities | $ | (2,381 | ) | $ | - | |||
| Financing Activities | $ | 1,825 | $ | - | ||||
Operating Activities
Net cash provided by operating activities in the six months ended June 30, 2024 was $551 compared to cash of $5,300 used in operating activities in the six months ended June 30, 2023, an improvement of $5,851. The improvement was primarily the result of the $15,264 reduction in the net loss, including noncontrolling interest, in the six months ended June 30, 2024 compared to the prior period. The improvement in the six months ended June 30, 2024 was partially offset by certain noncash items in the 2023 period, including: (i) the loss from PIK Note Amendment and 2022 Debenture Release of $3,521, (ii) increased stock-based compensation of $1,486, (iii) an increase in amortization of consulting fees paid in common stock of $2,120 and (iv) impairment of assets of $2,633, among other items.
| 41 |
Investing Activities
Investing activity in the six months ended June 30, 2024 used cash of $2,381. Cash of $2,221 was used to acquire an epigenetic software APP under the KR8 Agreement and the cash of $259, net of cash acquired, was used to purchase of Myrtle. No cash was used or provided by investing activities in the three months ended June 30, 2023.
Financing Activities
Net cash of $1,825 was provided by financing activities in the six months ended June 30, 2024 from the issuances of promissory notes, including a $265 promissory note issued to RHI for the purchase of Myrtle. No cash was used or provided by financing activities in the six months ended June 30, 2023.
Off-Balance Sheet Financing Arrangements
We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.
We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any non-financial assets.
Contractual Obligations
Our contractual obligations as of June 30, 2024 include (in thousands):
| Amounts Due by Period | ||||||||||||||||||||
| (Dollars in thousands) | 1 Year | 2 - 3 years | 4 - 5 years | More than 5 years | Total | |||||||||||||||
| KR8 Agreement (a) | $ | 2,322 | 4,450 | 4,450 | - | $ | 11,222 | |||||||||||||
| Other license agreement (b) | 40 | 40 | 20 | - | 100 | |||||||||||||||
| Note payable (c) | 8,376 | - | - | - | 8,376 | |||||||||||||||
| Related Parties Payable (d) | 294 | - | - | - | 294 | |||||||||||||||
| Right-of-use lease liability (e) | 420 | 840 | 840 | 420 | 2,520 | |||||||||||||||
| Management Agreement with RHI (f) | 180 | 360 | 360 | - | 900 | |||||||||||||||
| Supplier and other commitments | 54 | - | - | - | 54 | |||||||||||||||
| Total | $ | 11,686 | 5,690 | 5,670 | 420 | $ | 23,466 | |||||||||||||
| (a) | Amount due under KR8 Agreement include $2,000 for initial license and development fees, $50 per month for maintenance fees and minimum royalty payments. Perpetual management and royalty fees are projected through five years. |
| (b) | License agreement remains in place until the licensor’s patents expire or are abandoned. Amounts do not include development milestones that have not been reached as of June 30, 2024. |
| (c) | Represents the principal and interest balance as of June 30, 2024 for various notes payable, including the Senior PIK Notes in the amount of $4,707, which are past due. The Senior PIK Notes are subject to prepayment penalties and interest is paid through the issuance of additional Senior PIK Notes. The ultimate amount required to settle the Senior PIK notes will vary depending on when they are settled. Notes payable are more fully discussed in Note 9 of the accompanying unaudited condensed consolidated financial statements. |
| (d) | Represents the principal and interest balance as of June 30, 2024 of Promissory notes 1 and 2 due to related parties. Promissory note 1 does not bear interest and Promissory note 2 accrues interest in arrears at a rate of 13.25% per annum. The notes are due on demand, and in the absence of any demand, one year from the issuance date and may be prepaid, in whole or in part, without penalty at any time. |
| (e) | Facilities lease between Myrtle and RHI beginning June 14, 2024 for a term of one year with annual options to renew for up to 5 years. Initial monthly base rental amount is $35 with annual rental increases equal to the greater of 3% and the consumer price index. |
| (f) | Management agreement between Myrtle and RHI dated June 1, 2024 wherein RHI agreed to provide management and consulting services to Myrtle for a management fee of $15 per month. The agreement can be terminated by either party without cause on thirty days written notice to the other party. |
| 42 |
Critical Accounting Policies
The preparation of the unaudited condensed consolidated financial statements and related notes included under “Item 1. Financial Statements” and related disclosures in conformity with GAAP. The preparation of these unaudited condensed consolidated financial statements requires the selection of the appropriate accounting principles to be applied and the judgments and assumptions on which to base accounting estimates, which affect the reported amounts of assets and liabilities as of the date of the balance sheets, the reported amounts of revenue and expenses during the reporting periods, and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time such estimates are made. Actual results and outcomes may differ materially from our estimates, judgments, and assumptions. We periodically review our estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates are reflected in the unaudited condensed consolidated financial statements prospectively from the date of the change in estimate.
We define our critical accounting policies and estimates as those that require us to make subjective judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific manner in which we apply those principles. We believe the critical accounting policy used in the preparation of our financial statements which required significant estimates and judgments is as follows:
Going Concern
Our history of losses requires management to critically assess our ability to continue operating as a going concern. For the six months ended June 30, 2024 and 2023, we incurred net losses to common stockholders of $4,633 and $21,398, respectively. As of June 30, 2024, we had a working capital deficit and a total stockholders’ deficit of $20,817 and $16,167, respectively. While cash of $551 was provided by operating activities for the six months ended June 30, 2024, cash of $5,300 was used in operating activities for the six months ended June 30, 2023. As of June 30, 2024, we had $33 of available cash and cash equivalents.
On a quarterly basis, we assess going concern uncertainty for our condensed consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date our condensed consolidated financial statements are issued or are available to be issued (the “look-forward period”). Based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections, and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, among other factors, and our ability to delay or curtail those expenditures or programs within the look-forward period, if necessary. Until additional equity or debt capital is secured and the Company begins generating sufficient revenue, reducing losses, and improving future cash flows, there is substantial doubt about the Company’s ability to continue as a going concern. The Company will continue ongoing capital raise initiatives and has demonstrated previous success in raising capital to support its operations.
During the first quarter of 2023, we completed the sale of FOXO Life Insurance Company in order to gain access to the cash held as statutory capital and surplus at FOXO Life Insurance Company, which we used to fund a portion of our operations during 2023. To fund our operations, we continue to (i) pursue additional avenues to capitalize the Company, (ii) pursue strategic operating companies, including companies pursuant to two stock exchange agreements entered into on June 10, 2024, which are more fully discussed in Note 5 to the unaudited condensed consolidated financial statements included in this report, and (iii) commercialize our products to generate revenue.
As previously disclosed, on September 20, 2022, we issued the Senior PIK Notes in an aggregate principal amount of $3,457, each with a maturity date of April 1, 2024. Pursuant to the terms of the Senior PIK Notes, commencing on November 1, 2023, and on each one-month anniversary thereof, we are required to pay the holders of the Senior PIK Notes an equal amount until their outstanding principal balance has been paid in full on the Maturity Date, or, if earlier, upon acceleration or prepayment of the Senior PIK Notes in accordance with their terms. We failed to make the payments due on November 1, 2023 and on each one-month anniversary thereof, which constitutes an event of default under the Senior PIK Notes. We are in discussions with the holders of the Senior PIK Notes with respect to certain amendments to the Senior PIK Notes to cure the event of default. However, there has been no agreement with the Senior PIK Note holders that would cure the event of default.
| 43 |
Compliance with NYSE American Continued Listing Requirements
On April 17, 2024, the Company received an official notice of noncompliance from the New York Stock Exchange (“NYSE”) stating that it was not in compliance with NYSE American continued listing standards due to the failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Delinquent Report”) by the filing due date of April 16, 2024 (the “Filing Delinquency”). With the filing of the Delinquent Report and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, the Filing Delinquency was cured.
On June 10, 2024, the Company received an official notice of noncompliance from NYSE stating that the Company is not in compliance with NYSE American continued listing standards due to an outstanding balance of listing fees over 180 days old and NYSE provided the Company until June 7, 2024 to provide payment before the Company would become subject to the noncompliance procedures. The Company failed to pay the fee by June 7, 2024, which was extended to August 9, 2024. On August 7, 2024, the Company received a letter from NYSE stating that the Company is back in compliance with the NYSE American continued listed standards pertaining to timely payment of listing fees set forth in Section 1003(f)(iv) of the NYSE American Company Guide. The letter acknowledged that the Company has paid its outstanding balance of fees.
On July 10, 2024, the Company received an official notice of noncompliance from NYSE stating that the Company is not in compliance with Section 1003(a)(ii) of the Company Guide since it reported stockholders’ deficit of ($14.9) million as of March 31, 2024, and losses from continuing operations and/or net losses in its three most recent fiscal years ended December 31, 2023. The Company is now subject to the procedures and requirements set forth in Section 1009 of the Company Guide.
On June 12, 2023, the Company received an official notice of noncompliance from NYSE Regulation stating that the Company is below compliance with Section 1003(a)(i) in the NYSE American Company Guide since the Company reported stockholders’ deficit of $30 at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. As required by the notice, on July 12, 2023, the Company submitted a compliance plan (the “Plan”) to NYSE advising of actions it has taken or will take to regain compliance with the NYSE American continued listing standards by December 12, 2024, and if NYSE accepts the Plan, the Company will have until December 12, 2024 to comply with the Plan. Should the Plan not be accepted, or the Company be unable to comply with the Plan, then it may make it more difficult for the Company to raise capital and the Company will be delisted in the event it is unable to cure the noncompliance by December 12, 2024.
However, we can provide no assurance that these actions will be successful or that additional sources of financing will be available to us on favorable terms, if at all. As such, until additional equity or debt capital is secured and we begin generating sufficient revenue, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of the accompanying unaudited condensed consolidated financial statements. Assuming we are successful in closing the stock exchange agreement with RHI entered into on June 10, 2024, which is more fully discussed in Note 5 to the accompanying unaudited condensed consolidated financial statements, we believe we will be able to fund our operations until the end of December 31, 2024. In any event, if we are unable to fund our operations we will be required to evaluate further alternatives, which could include further curtailing or suspending operations, selling the Company, dissolving and liquidating its assets or seeking protection under the bankruptcy laws. A determination to take any of these actions could occur at a time that is earlier than when we would otherwise exhaust our cash resources.
Factors That May Adversely Affect our Results of Operations
Our results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond our control. Our business could be impacted by, among other things, downturns in the financial markets or in economic conditions, increases in oil prices, inflation, increases in interest rates, supply chain disruptions, declines in consumer confidence and spending, the effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflicts in Ukraine and Israel. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
| 44 |
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our principal executive officer and our principal financial and accounting officer (the “Certifying Officers”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Under the supervision and with the participation of our management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were not effective as of June 30, 2024.
Management became aware of the material weaknesses described above during the preparation of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. To address the material weaknesses, the Company performed additional analyses and other procedures, including reviewing the terms of its common stock warrants and the methods used to determine the fair value of its common stock warrants as presented in its unaudited condensed consolidated financial statements at and as of June 30, 2024. However, the material weaknesses have not been fully remediated as of the filing date of this report.
Changes in Internal Control over Financial Reporting
There has been no change in the Company’s internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during the Company’s quarter ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
| 45 |
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
SEC Investigation
On March 3, 2023, the Company received a document request from the SEC indicating that the SEC was conducting an investigation regarding the Company and sought documents concerning (1) Jon Sabes’ termination as CEO, (2) Jon Sabes’ resignation from the Company’s board of directors, and (3) Steven Sabes’ termination as COO, and is voluntarily responding to the SEC’s request. According to the SEC’s request, its investigation does not mean that the SEC has concluded that anyone violated the law or that the SEC has a negative opinion of the Company or any person, event, or security.
On July 9, 2024, the Company received a letter from the SEC has concluded the investigation and, based on the information it had as of that date, it does not intend to recommend an enforcement action against the Company.
ITEM 5. OTHER INFORMATION
During
the quarter ended June 30, 2024, no director or officer
ITEM 6. EXHIBITS
The following exhibits are filed as part of, or incorporated by reference into, this Report.
| Exhibit No. | Description | Included | Form | Referenced Exhibit |
Filing Date | |||||
| 10.1 | Exchange Agreement with Smithline Family Trust II dated May 28, 2024 | Filed Herewith | ||||||||
| 31.1 | Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed Herewith | ||||||||
| 31.2 | Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed Herewith | ||||||||
| 32.1# | Certification of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350. | Furnished Herewith | ||||||||
| 101.INS | Inline XBRL Instance Document. | Filed Herewith | ||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | Filed Herewith | ||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | Filed Herewith | ||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | Filed Herewith | ||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | Filed Herewith | ||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | Filed Herewith | ||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | Filed Herewith |
| # | This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
| 46 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| FOXO TECHNOLOGIES INC. | ||
| Date: August 19, 2024 | /s/ Mark White | |
| Name: | Mark White | |
| Title: | Interim Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: August 19, 2024 | /s/ Martin Ward | |
| Name: | Martin Ward | |
| Title: | Interim Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| 47 |